« March 2005 | Main | May 2005 »

April 29, 2022

Research and Markets: Diagnostic Electro-Medical Equipment Market Analysis 2004-2005

Research and Markets (http://www.researchandmarkets.com/reports/c16496) has announced the addition of Diagnostic Electro-Medical Equipment Market 2004-2005 to their offering.

(PRWEB) April 29, 2022 -- Research and Markets (http://www.researchandmarkets.com/reports/c16496) has announced the addition of Diagnostic Electro-Medical Equipment Market 2004-2005 to their offering.

This informative marketing report, covers 37 product categories for market trends, market size in value/quantity, and market share for FY2003 and 2004 and forecasts up to FY2007, sales performance by product & strategies of leading manufacturers/sales agencies, and financial & product information of more than 230 players.

The product categories include electrocardiographs (ECG), patient monitoring systems, polygraphs, electroencephalographs (EEG), medical thermographs, endoscopes, handheld endoscopes, extrafine endoscopes, ultrasound imaging systems, intra-vascular ultrasound systems (IVUS), computed tomography scanners (CT), magnetic resonance imaging scanners (MRI), intra-coronary ultrasound systems (ICUS), angiographs, X-ray systems for surgery and diagnosis, nuclear medicine diagnosis systems, magnetoencephalographs (MEG), bone densitometers, picture archiving and communication systems (PACS), laser imagers, automatic processors, thermal video printers, computed radiographs (CR)/digital radiographs (DR), pulse oximeters, cerebral oxygen saturation monitors, and blood-flow meters, etc.

This report is particularly relevant for manufacturers, and general sales agents.

For more information visit http://www.researchandmarkets.com/reports/c16496

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980

Posted by Industrial-Manufacturing at 07:03 AM | Comments (0)

April 28, 2022

Radical Randy™, New 3-D MediKin™ Teaching Aide, Helps Children Understand Asthma and Take an Active Role to Control It

Asthma is the most prevalent chronic condition in children, occuring in approximately 7-10% of the population. Pediatric asthma patients (and their parents) are often reluctant to follow the prescribed regimen of controller medications. When the symptoms abate, they often cease or forget the medications. With Radical Randy™, a new MediKin™ teaching aide from Legacy Products, health care educators can explain and actually show children what happens in their lungs and airways during an asthma attack. As a result, children understand why regular medication is important (even when they feel fine) and they begin taking an active role in monitoring and controlling their asthma.

(PRWEB) April 28, 2022 -- Asthma is the most prevalent chronic condition in children. It occurs in approximately 7-10% of the pediatric population. Pediatric asthma patients (and their parents) are often reluctant to follow the prescribed regimen of controller medications. When their symptoms abate, they often cease or forget the medications. Radical Randy™, a new MediKin™ teaching aide from Legacy Products, helps educators explain and actually show children what happens in their lungs and airways during an asthma attack. As a result, children begin taking an active role in monitoring and controlling their asthma.

Developed in collaboration with the Pediatrics Asthma Team at the University of Texas Medical Branch (UTMB) in Galveston, Radical Randy’s chest opens to reveal a healthy lung depicted on the right and a lung with inflamed airways on the left. Randy’s lungs incorporate pockets with removable bronchioles. The bronchioles can be inflated by squeezing the bulb pump that is connected to them by plastic tubing. Air can be felt moving freely through the healthy bronchiole’s airway demonstrating the positive affect of daily controller medications. In the inflamed and swollen bronchiole, air gets blocked, demonstrating why breathing is difficult or nearly impossible during asthma flare-ups. Mucus accumulation can also be demonstrated by inserting the provided green "mucus" into the swollen bronchiole, further blocking its airway.

Radical Randy™ is constructed of soft, durable fabric with embroidered details. Standing just 3-feet tall, the MediKin™ is lightweight and portable. It is useful for home visits, one-on-one instruction, group clinics and school education programs.

A part of Legacy’s Asthma Education Program, the Radical Randy™ MediKin™ is available in either dark or neutral skin tone and comes with instructor guides in English and Spanish, a videotape demonstration class, clothing (including shirt, shorts, shoes and socks), a pair of Expression Adapters to change Randy’s facial appearance from happy to anxious, a jar of green "mucus", a magnifying glass and a zippered carrying case.

In a series of three field trials of the Legacy Asthma Program, administered by UTMB, the teaching time for basic asthma pathophysiology was reduced from 27 minutes to as little as 13 minutes, depending on the educator’s skill. Using the Radical Randy™ MediKin™, educators quickly demonstrated the abstract concepts of airway inflammation, mucus accumulation, bronchoconstriction and their relations to symptoms and medication. The MediKin™ teaching aides also helped the instructors reduce language, emotional and learning barriers.

Radical Randy™ is part of a line of 3-D, interactive, medical teaching tools and instructional programs produced by Legacy Products, Inc. Legacy’s light-weight, fabric MediKins and interchangeable adapters, many of which accommodate actual medical equipment, are used to educate patients, caregivers and health care staff about medical conditions and treatments. For more information on Radical Randy™ or their other products, contact Legacy Products, Inc., P.O. Box 267, Cambridge City, IN 47327, www.legacyproductsinc.com

Posted by Industrial-Manufacturing at 01:34 AM | Comments (0)

Timeless Medical Systems Releases Version 2.0 of the Timeless Laboratory Information Management System (LIMS)

Timeless Medical Systems releases version 2.0 of the Timeless Laboratory Information Management System (LIMS), a complete information management system for all laboratory disciplines.

(PRWEB) April 28, 2022 -- Timeless Medical Systems today announced the release of the Timeless Laboratory Information Management System (LIMS) version 2.0.

The Timeless LIMS is a comprehensive laboratory information management system for all laboratory disciplines. The Timeless LIMS is an advanced system built using the latest scalable database foundation, incorporates customizable applications, supports multiple users in more than one geographic area with secure access to the data and provides an intuitive and efficient workflow enabling fast and accurate turn around of results. The Timeless LIMS provides hospital and reference laboratories, as well as regional and state/provincial health services providers with a complete end to end solution.

“Timeless is very pleased to announce the release of version 2.0 of our Laboratory Information Management System,” stated Justin MacLeod, President of Timeless Medical Systems. “This latest release of the Timeless LIMS incorporates significant new feature sets into our product including fully customizable application screens and forms, secure web enabled access to the central database and support for multiple laboratory departments, both internal/external and across multiple platforms. With version 2.0, the Timeless LIMS meets the mission critical objective of fast and accurate turn around enabling the highest possible quality results.”

Version 2.0 of the Timeless LIMS is available for implementation now. Interested parties may find contact information below.

About Timeless Medical Systems:
Timeless Medical Systems develops advanced software applications, hardware and information technology systems for Healthcare Professionals. Timeless Medical Systems' products include statistical information gathering, reporting and management applications for Cancer Registrars and Oncology Departments, blood product inventory management and tracking systems for Blood Labs/Banks, laboratory information management systems (LIS/LIMS), 9-1-1 communications systems, clinical speech diagnostic tools, as well as, sophisticated database management tools for health records security, back-up and data integrity.

For more information about Timeless Medical Systems, its products or services, please call 800-630-3730 or visit www.TimelessMedical.com.

Posted by Industrial-Manufacturing at 01:33 AM | Comments (0)

DDL Testing Services Demystifies Complex Package Validation Process - Shares Advice with Medical Device Manufacturers at Medcon 2005

DDL Inc., a leading package, product and material testing laboratory, will be presenting “Demystifying Medical Device Package Validation” at the Medcon 2005 Conference, April 27–28.

San Diego, CA (PRWEB) April 27, 2022 - http://www.testedandproven.com - Scott Levy, Package Engineer at DDL Inc., a leading package, product and material testing laboratory, will be presenting “Demystifying Medical Device Package Validation” at the Medcon 2005 Conference, April 27–28, Del Mar Fairgrounds Activity Center, San Diego, CA.


Demystifying Medical Device Package Validation is intended to help medical device manufacturers understand complex package validation processes, along with what it takes to satisfy regulatory requirements regarding sterile medical device packaging.

“Many medical device manufacturers struggle on a daily basis with what they need to do to set up a shelf-life package validation,” said Levy. “Many are unaware of how to satisfy industry standards such as ISO 11607.”

According to the ISO 11607 standard, the manufacturer “must ensure the product and package system combine to create a total product which performs efficiently, safely, and effectively in the hands of the user.”

Levy will answer ten frequently asked questions regarding the medical device package validation process, including which industry standards the package should adhere to and what each manufacturer should do to ensure the satisfaction of these requirements.

Levy will also share how DDL is helping manufacturers comply with ISO 11607 (Clause 7) via its PackReview service.

Join Scott Levy for “Demystifying Medical Device Package Validation”
Wednesday, April 27, 2005, at 11am - Bing Crosby Hall, Del Mar Fairgrounds Activity Center, San Diego, CA

For more information on complex package validation processes and the PackReview service, stop by the DDL booth #59 at Medcon or visit http://www.testedandproven.com/packreview.html

About DDL
DDL offers expert testing services that provide excellent documentation for package testing, material testing, product testing and HazMat testing. DDL package testing clients find peace of mind with the DDL reliable PackReview (SM) ISO 11607 clause 7 certification. DDL maintains full service testing labs in Minnesota and California.

Contact DDL at: http://www.TestedAndProven.com or call Scott Levy at 952-941-9226 ext.115.

Posted by Industrial-Manufacturing at 01:32 AM | Comments (0)

FDA Reply to Today Sponge Safety Questions Called Inadequate

The frequent irritation and increased risk of HIV infection that are associated with the use of the Today Contraceptive Sponge have not been adequately addressed by the 4/22/05 reply from the US FDA.

(PRWEB) April 27, 2022 -- The FDA's reply* to a petition about the safety of the Today Contraceptive Sponge did not adequately answer why the Sponge should again be sold. The Citizen’s Petition**, submitted by two public interest groups** *in April, 2000, describes the frequent irritation and disruptions of the vagina that can be expected by users of the Today Sponge. In addition to the immediate discomfort the Sponge may cause, the prolonged exposure of vaginal tissues to the high concentration of Nonoxynol 9 (N-9) in the Sponge can increase the risk of HIV infection.


In responding the concerns about irritation caused by the Today Sponge, the FDA cited a small study which suggested that another OTC vaginal contraceptive (Conceptrol (Ortho Pharmaceuticals)) was shown to be more irritating than the Sponge. Although such a reply offers little comfort to young women victimized by either product, among the major shortcomings of this industry sponsored study was the acknowledgement by the authors that they did not know if the 42 subjects actually used any of the contraceptive products as requested (1), undermining the credibility of any comparison on the matter of irritation.

When the Today Sponge was first released in 1983, an earlier Petition raised concern about a possible increase in the risk of TSS associated with the Today Sponge. Researchers at the FDA eventually demonstrated that risk and package warnings were added. In response to the concerns in the recent Petition about the increased risk of HIV infection associated with repeated use of the Today Sponge and other high dose vaginal products containing N-9, the FDA announced that new package labels would warn of HIV risk associated with the use of the Sponge.

Dr. Armand Lione, President of Associated Pharmacologists & Toxicologists, the chief author of the Sponge Petition, commented: “We are pleased that the FDA has improved the warnings given to women, but we don’t think that a contraceptive like the Today Sponge, that has a high failure rate and readily produces irritation, is what should be offered to the young people who need these products.”

* For more information on the FDA 4/22/05 reply, please contact: S. Galson, CEDER, at the US Food & Drug Administration.
** A copy of the 2000 petition is available on the FDA website (www.fda.gov)
*** The Empire State Consumer Association, Rochester NY 585-383-1317 co-authored the 2000 Citizen Petition.
(1) Poindexter et al: Contraception 53:147-153, 1996 see p. 148.

Posted by Industrial-Manufacturing at 01:32 AM | Comments (0)

Longmont LifeScience Thursday to Be Held May 12; Panel Will Discuss Investigational New Drug (IND) Applications & Issues

The Colorado BioScience Association (CBSA) will host Longmont LifeScience Thursday on May 12 from 3:30 p.m. until 6:00 p.m.at the Radisson Conference Center in Longmont, at 1900 Ken Pratt Blvd. The event will feature a panel discussion on "Investigational New Drug (IND) Applications & Issues" by a group of experts.

Longmont, CO (PRWEB) April 27, 2022 -- The Colorado BioScience Association (CBSA) will host Longmont LifeScience Thursday on May 12 from 3:30 p.m. until 6:00 p.m.at the Radisson Conference Center in Longmont, at 1900 Ken Pratt Blvd. The event will feature a panel discussion on "Investigational New Drug (IND) Applications & Issues" by a group of experts.

Panel members will include Dr. Ali Said Faqi, MPI Research, Inc., Mr. Bruce Feistner, OSI Pharmaceuticals and Dr. Dorothy Colagiovanni, Replidyne, Inc., with another panel member to be added. Dr. Colagiovanni will also act as moderator. Panelists will discuss pre-clinical, regulatory and clinical issues, as well as stumbling blocks.

CBSA members may attend at no cost. Non-member admission is $50, and a student discount is available.

Longmont LifeScience Thursday, held each quarter, began in 2003, and is designed to provide information and networking opportunities for those interested in the life science industry, including those involved or interested in biotechnology, medical devices, ag biotech, pharmaceuticals, research institutions and life science industries. The Longmont Area Economic Council is a founding sponsor of the event and John Cody, LAEC President, serves on the CBSA Program Committee. Denise Brown, Executive Director of CBSA, has been instrumental in developing new programs for the Association and raising its profile in Colorado.

This program is sponsored by the Longmont Area Economic Council and Pratt Management.

About the Longmont Area Economic Council
The Longmont Area Economic Council exists for the sole purpose of keeping the Longmont area economy strong. This is accomplished specifically by "actively supporting the creation and preservation of quality primary jobs." Primary employers are those who sell the majority of their goods and services outside the region. LAEC is a public/private partnership, governed by a Board of Directors made up of representatives from primary employers, the City of Longmont, and the business community at large. For more information, call (303) 651-0128, email e-mail protected from spam bots, or visit www.longmont.org.

About the Colorado BioScience Assocation
The Colorado BioScience Association is a not-for-profit corporation providing services and support for Colorado’s growing biosciences industry. Colorado is embarking on an aggressive plan to grow the state’s bioscience industry into one of the country’s premier bioscience clusters. CBSA enjoys the support of over 200 member organizations representing a range of bioscience companies dedicated to solving problems and developing products as well as companies providing key services to the bioscience industry and research institutions. CBSA works closely with the state and local policy makers to represent the interests of the bioscience industry. A critical component for Colorado to become one of the country’s top bioscience clusters is a supportive legislative and regulatory environment. The Colorado BioScience Association actively works to achieve these results. For more information, call 720-859-4153, email e-mail protected from spam bots, or visit www.cobioscience.com.

Speaker Bios
Dr. Ali Said Faqi, Director of Developmental & Reproductive Toxicology at MPI Research in Kalamazoo, Michigan. Before joining MPI Research he was a senior Scientist at IITRI in Chicago, Illinois and Allergan Pharmaceuticals in Irvine, California. Dr. Faqi is also an adjunct Professor at the University Palermo, Italy. Dr. Faqi received his DVM degree from the Somali National University in Mogadishu, Somalia and Diploma of Specialization in Experimental Pharmacology at University of Milan in Italy. He received his PhD from the University of Leipzig in Germany. He worked as a Postdoctoral Fellow/Research Scientist at the Free University of Berlin, in Germany, Thomas Jefferson University in Philadelphia and Morehouse School of medicine in Atlanta.

Mr. Bruce Feistner, Regulatory Affairs Manager at OSI Pharmaceuticals. He joined NeXagen Pharmaceuticals in 1993 and has worked through the various permutations of the Boulder company as it evolved from NeXagen to NeXstar Pharmaceuticals to Gilead Sciences and finally OSI Pharmaceuticals. During that period Mr. Feistner has worked primarily with oncology drug products and has witnessed the transformation from traditional chemotherapeutics to targeted therapies. He is responsible for preparing and/or overseeing regulatory submissions for investigational and commercial products on a global basis.

Dr. Dorothy Colagiovanni, novel antibiotic development toxicologist, Replidyne, Inc. Prior to working at Replidyne, she was a Research Investigator at OSI Pharmaceuticals where she was involved with development of targeted cancer therapeutics and managed the toxicology group which conducted GLP compliant studies for regulatory submissions. She has also worked for Amgen in the area of immunotoxicology assessment of novel proteins and at Gilead Sciences in the Anti-Infectives Division. Dr. Colagiovanni attended the University of Vermont and completed a Bachelor of Science degree in Medical Technology. Her graduate training took place at the University of Colorado Health Sciences Center where she earned a doctorate in Molecular Toxicology. She is board certified as a Diplomate of the American Board of Toxicology and has written numerous toxicology documents to support IND submissions and Investigator’s Brochures.

Posted by Industrial-Manufacturing at 01:31 AM | Comments (0)

April 26, 2022

Baxa Features Exacta-Med® And PhaSeal® Systems For Safe Handling And Administration Of Fluid Drugs At Interphex 2005

Baxa Corporation will present its proprietary systems designed to enhance the safety and efficiency of fluid medication handling and delivery at the 26th annual Interphex Conference and Exhibition -- April 26 – 28 at the Jacob K. Javits Center in New York. Its PhaSeal and Exacta-Med products offer added value to packaged pharmaceuticals as part of a complete drug delivery system.

New York, NY (PRWEB) April 26, 2022 -- At the 26th annual Interphex Conference and Exhibition, Baxa Corporation will present its proprietary systems designed to enhance the safety and efficiency of fluid medication handling and delivery. Its PhaSeal and Exacta-Med products offer added value to packaged pharmaceuticals as part of a complete drug delivery system.


PhaSeal, the only closed system for safe handling of antineoplastic and other hazardous drugs, has been documented to reduce or eliminate human exposure to toxic hazards in the workplace. The system allows healthcare workers to reconstitute, transport, and administer hazardous drugs without risk of environmental contamination. Closed systems are recommended by the National Institute for Occupational Safety and Health (NIOSH) in its 2004 Alert to prevent occupational and environmental exposure to hazardous drugs.

Exacta-Med Dispensers provide safe oral and enteral medication delivery by eliminating the risk of wrong-route administration. The system’s non-luer components cannot actuate a needleless valve or connect to a hypodermic needle or fitting. Oral dispensers are recommended by the Institute for Safe Medication Practices (ISMP) to reduce the opportunity for med errors.

Interphex 2005, held April 26 – 28 at the Jacob K. Javits Center in New York, brings together global companies serving the pharmaceutical and biotechnical industries. This year’s exhibition is paired with an application-oriented conference to help industry professionals develop critical on-the-job skills.

“Interphex offers Baxa an opportunity to find pharmaceutical partners,” states Joyce Federer, Director of OEM Sales, “Our goal is to help other manufacturers create greater product value for mature products, improve the safety of their medication delivery, or to improve the outcomes of their clinical trials. Baxa, with thirty years’ experience in the hospital pharmacy, is in a unique position to offer regulatory expertise and market knowledge that can assist other companies in the development of specialized products for drug delivery applications, or to add value through improved patient safety and compliance.”

Founded in 1975, Baxa Corporation built its reputation by designing niche products that provide solutions for the transfer, delivery, packaging and administration of fluid medications in hospital pharmacy and alternate-site settings worldwide. The company is certified to the quality standards for ISO 13485 and EN46001.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.

About Interphex 2005
The world’s largest and most comprehensive pharmaceutical conference and exhibition is held annually at the Jacob K. Javits Center. Sponsored by Reed Exhibitions, the meeting features 1,000 global exhibitors in the areas of PharmaManufacturing, PharmaSourcing & Services, PharmaIT and PharmaFacilities. Further information is available at http://www.interphex.com.

Contacts:
Marian Robinson
Vice President, Marketing
Baxa Corporation
800.567.2292 ext. 2157
or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben
APR
Absolutely Public Relations
303.984.9801
or 303.669.3558
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 07:22 AM | Comments (0)

BC Tech product - EZ-IO(tm) - wins 2005 Medical Design Excellence Award.

BC Tech, a developer and manufacturer of medical products announces that the EZ-IO(tm) product, developed for VidaCare Corporation has been selected as a winner of 2005 Medical Design Excellence Award.

Santa Cruz, California- April 25, 2022 (Newswire.Net via PRWeb)

BC Tech, a leading FDA certified contract developer and manufacturer of medical products in Santa Cruz, California since 1996, is proud to announce that the EZ-IO(tm) product, designed and developed by BC Tech for VidaCare Corporation has been selected as a winner of the prestigious 2005 Medical Design Excellence Award. The awards ceremony will be held in New York on June 14th in conjunction with the 2005 Medical Design & Manufacturing (MD&M-East;) conference.

The MDEA competition is the premier awards program for the medical technology community, recognizing the many people behind the scenes, the engineers, scientists, and designers, who are responsible for the groundbreaking innovations that are changing the face of healthcare. This program is presented by Canon Communications LLC, and supported by the Human Factors and Ergonomics Society [HFES, an interdisciplinary organization of professionals involved in the human factors field.

VidaCare's EZ-IO(tm) provides emergency medical technicians with a simple and rapid means to initiate intraosseous (IO) infusions. EZ-IO(tm) is a small battery-powered device that safely penetrates a patient's bone with a hollow drill to provide immediate IO access for any drug or fluid. In cases such as shock, trauma or cardiac arrest, patient's peripheral veins collapse making standard IV techniques difficult or impossible. Bone marrow (the intraosseous area) is actually a non-collapsible vein, through which drugs and other fluids can be administered.

"BC Tech relies on its dedicated staff of 60 engineers, designers, manufacturing and quality professionals to offer the best innovative products and services to our clients ranging from new start-ups to well established companies. We have recently completed the expansion of our manufacturing facility to accommodate the growing needs of our clients and the industry at large," said Ben Clawson, founder and CEO of BC Tech.


For more information contact:

DeeDee Fernandez
Ph - 831-459-6467
Fax - 831-459-6465
Cell -831-818-4223
e-mail protected from spam bots


BC Tech can be found on the Internet at www.bctechinc.com

Posted by Industrial-Manufacturing at 07:21 AM | Comments (0)

April 25, 2022

Find Out Whether You Qualify For Free Diabetic Supplies.

FreedoMed - Nation's leading mail-order distributor of brand name diabetic supplies including Freestyle, Accu-Check and OneTouch; now allow you to apply for free diabetic supplies. Anyone who are interested can do so at: http://www.dpbolvw.net/click-1588997-10384199 This online application form also includes the Medical Authorization.

(PRWEB) April 23, 2022 -- Around the country, diabetes affects an estimated 18.2 million Americans, and the number rises each year. To briefly explain, diabetes is a malfunction of the Langehans Glands, situated in the Pancreas, to produce Insulin. Insulin enables the body to dissolve the sugar into energy for the muscles. So, for a diabetic patient, the sugar stays in the blood. That causes the body tissues to get tender and they start deteriorating faster than normal. There are two type of diabetes:

TYPE I DIABETES – usually occurs in children and young adults, but can develop at any age. People with type I diabetes need insulin every day.

TYPE II DIABETES – usually occurs in adults who overweight, are in their middle or later years, and have family members with diabetes. Many people can control this type of diabetes with diet, weight loss, and exercise. Some will also need diabetes pills or insulin.

To take care of type I or type II diabetes, a person needs to eat healthy foods, exercise, take medicine if it is prescribed, and see a doctor on a regular basis. Without diagnosis and treatment, diabetes may result in long-term complications, such as blindness, heart attack, stroke, kidney disease or amputation.

In the United States, about 100 billion dollars are spent on diabetes care in every year.

According to a Clark County research in 1999 (Source: http://www.ag.unr.edu/uced/reports/technicalreports/fy1998_1999/9899_03rpt.pdf), on average, patients seeking medical treatment for diabetes directly spend 3.7 times more per year than patients seeking routine medical treatment, $10,071 compared to $2,669. This can be a substantial cost for some family with diabetes sufferer among their family members. For these family, any source of low cost medical supplies must be a most welcome option for them.

One of such organization is FreedoMed - Nation's leading mail-order distributor of brand name diabetic supplies. They carry all of the leading brands of diabetic testing supplies including Freestyle, Accu-Check and OneTouch. Most of their customers receive their supplies delivered to their door at no cost. Customer also can go to their website: http://www.dpbolvw.net/click-1588997-10384199 to apply for free diabetic supplies. This online application form also includes the Medical Authorization.

Free doMed also accept Medicare and Medicare assignment as well as Private Insurance/Major Medical/Group Health Plans: Accept most plans in all 50 states with the exception of HMO's.

Posted by Industrial-Manufacturing at 05:45 AM | Comments (0)

Zorich Technical Consulting and Publishing (ZTC) Partners with Steton Technology Group

Zorich Technical Consulting and Publishing (ZTC) has signed on as a channel partner for Steton Technology Group to work with them on the sale and implementation of the Steton Enterprise Quality and Safety Systems for the consumer product, food, chemical, medical device, biotech and diagnostic industry verticals. Current Steton clients include Carlson Restaurants, CNS/Foodsafe, Correction Corporation of America, General Mills, Hormel Foods Corporation, JohnsonDiversey, Kegel’s Produce, SkyWest Airlines, Sodexho, State of Louisiana, Sunny Fresh Division of Cargill, The Holland Inc. and Tyson Foods.

Brookfield, IL (PRWEB) April 22, 2022 -- Zorich Technical Consulting and Publishing (ZTC) has signed on as a channel partner for Steton Technology Group to work with them on the sale and implementation of the Steton Enterprise Quality and Safety Systems for the consumer product, food, chemical, medical device, biotech and diagnostic industry verticals. Current Steton clients include Carlson Restaurants, CNS/Foodsafe, Correction Corporation of America, General Mills, Hormel Foods Corporation, JohnsonDiversey, Kegel’s Produce, SkyWest Airlines, Sodexho, State of Louisiana, Sunny Fresh Division of Cargill, The Holland Inc. and Tyson Foods.

Principals John Zorich and Terry Cawley each have over 20 years experience in various industries. ZTC provides a number of consulting and training services to regulated industries. Their services include:
- GMP, Quality, QSR, Safety and ISO audits
- Regulatory, SPC and Statistics Training
- Compliance and Regulatory Consulting and Training
- Process Analysis and Optimization
- Mass Customization and Supply Chain Optimization
- Product Development and Enhancement
- Market Analysis and Development
- Training Curriculum and Course Development

Terry Cawley is also CEO of Athletique Inc. More information regarding Zorich Technical Consulting can be found by visiting their website at www.johnzorich.com

Steton Technology Group, established in 1996, is the leading provider of mobile data collection and reporting software. With the release of Steton Quality Suite (SQS) in 2000, Steton introduced technology that changed the way the entire profession of quality and safety specialists manage risk and monitor regulatory compliance. Instead of conducting inspections and audits using the traditional, but less efficient paper and pencil method, data collection can now be performed utilizing Steton’s software installed on handheld computer devices and desktop computers with the ability to upload the results, from anywhere in the world, at any time, into SQS.

More information on Steton can be found at www.steton.com.

Posted by Industrial-Manufacturing at 05:45 AM | Comments (0)

April 22, 2022

830Laser Responds to FDA's Recent Pain-Relief Drug Caution

Dr. Anthony Pirritano believes cold laser therapy is the best alternative to drug therapy.

Murietta, CA (PRWEB via PR Web Direct) April 20, 2022 – Recent pain relief drug recalls have left fewer options for relief of muscular and joint pain, but according to Dr. Anthony Pirritano, DC, 830Laser.com has the solution – cold laser therapy treatment.

Clinicians have used the 830Laser to treat a plethora of ailments with amazing results. Certainly the 830Laser renders removal of several anti-inflammatory pain relievers from the market a lesser issue to those seeking relief from muscular and joint pain. The 830Laser is distributed by 830Laser, LLC, in Murrieta, CA, www.830laser.com.

The widely prescribed painkiller Bextra was pulled from the market this month due to findings that it may result in an increased chance of heart attacks. The government also ordered 19 additional prescription anti-inflammatory painkillers — from Celebrex to high-dose naproxen — to carry tough new warnings that they may increase the risk of heart attacks and strokes. This leaves fewer options for relief of muscular and joint pain.

"Fortunately there is an alternative that is a better solution to those in need of pain relief," states Dr. Pirritano, DC.

Cold laser therapy with the 830Laser is the best alternative to drug therapy. Cold laser therapy has been recognized as an effective means of not only providing pain relief but also the acceleration of tissue healing and increased tissue strength. Accelerated tissue healing is one benefit of laser therapy not present with anti-inflammatory drug therapy.

With the recent FDA advisories on the use of pain relief drugs—both over-the-counter and prescription— Dr. Pirratano states that now more than ever is the time for a treatment with no side effects and proven results.

Patients and doctors wishing to learn more about receiving relief from muscular and joint pain from 830Laser treatment can visit www.830Laser.com or call the 830 Laser Support Center at 800-513-7060.

830 Laser Support Center
1-800-513-7060

Posted by Industrial-Manufacturing at 07:24 AM | Comments (0)

Buxton and The Paquin Group join forces in Healthcare Retail Market

Buxton, a top source of customer analytics, announced the signing of a strategic alliance with The Paquin Group, a leading provider of healthcare retail consulting services.

Fort Worth, TX (PRWEB) April 22, 2022 -- Buxton, a top source of customer analytics, announced the signing of a strategic alliance with The Paquin Group, a leading provider of healthcare retail consulting services.

The Paquin Group has worked extensively with healthcare organizations nationwide in educating executives on opportunities in retail, including the sales of convenience and healthcare products as well as traditional gift shop items. Buxton will provide psychographic data and its proprietary drive-time analysis to clients of the Paquin Group.

This information will allow hospital executives to determine the best course for retail at their facilities.

The healthcare products market is one of the largest product retail niches with total annual sales approaching $350 billion annually. Currently, hospitals and healthcare organizations help patients identify the many healthcare products needed, but generally do not sell them. Many hospitals in the United States have very high volumes of traffic generated by patient admissions, visitors and staff. In many cases, this traffic is comparable to that found at traditional shopping malls.

“Our mission is to help our clients convert this high value traffic into financial benefit and improved patient outcomes,” says Paquin Group CEO Tony Paquin. “We believe hospitals need to apply scientific analysis to determine if they should be in retail, and if so, to decide upon the best retail products for their customers. Buxton brings the necessary data to the process.”

In the alliance with Paquin, Buxton will perform customer analysis to quantify the need for retail services in each healthcare facility. Buxton will also help determine what products to sell at each facility. "This alliance strengthens our place in the healthcare retail marketplace,” says Buxton CEO Tom Buxton. “Our organizations strongly complement each other. Together, we will provide unsurpassed service to our clients.”

Paquin and Buxton will cooperate in sales, marketing and healthcare industry initiatives for this venture.

About Buxton
Since 1994, Buxton has been the industry leader in customer analysis for the retail industry. Buxton draws from its database of over 100 million households to identify individual customer’s lifestyles, behavior patterns and buying habits to accurately advise retail and restaurant chains where to locate new stores. Among its 1,000 clients are Pier 1 Imports, Bass Pro Shops, Hugo Boss, Dave & Buster’s, Mimi Maternity and The Container Store. Fast Company magazine recently named Tom Buxton, president and CEO of Buxton, to its 2005 Fast 50. Each year, the magazine recognizes 50 remarkable people for their leadership and innovation.

About The Paquin Group
The Paquin Group is an alliance of industry leading experts and resources created to assist hospitals in the implementation of healthcare retail strategies. The company’s core mission is to increase revenue opportunities and minimize risks for healthcare organizations. As Medicare reimbursement rates continue to be pressured downward and expenses rise, new sources for non-reimbursed revenues are becoming essential to the financial viability of hospitals. Paquin helps hospitals identify and implement these new retail revenue strategies.

Posted by Industrial-Manufacturing at 07:24 AM | Comments (0)

April 21, 2022

REOMED Medical Isolation transformers Provide an Ungrounded Power Supply System that Improves the Reliability of Supply Voltage and Reduces the Leakage Current

REOMED ensures that there is no direct connection between earth and the live/neutral conductors.

(PRWEB) April 21, 2022 -- In medical applications, it is required that the contact parts are electrically "floating", which means that they are supplied from a source of power where the neutral line is isolated from the earth line. The REOMED ensures that there is no direct connection between earth and the live/neutral conductors. This has several benefits, notably, in the case of an insulation fault, only a small leakage current will flow and the line fuse will not trigger, which allows the supply to be maintained even under a single fault condition. The REOMED range has built in inrush, short circuit and thermal protection. It uses a high quality toroidal transformer, which ensures that magnetic stray fields are minimized and will not affect other, nearby medical equipment. A separately earthed, shielded winding helps to reduce mains borne interference. The isolation between the live and neutral lines and all earth points is tested at 4kV for 1min. To ensure that all equipment in an installation is at the same potential, the REOMED units are also supplied with potential equalizing POAG connectors, which enable all equipment to be physically bonded, thus ensuring that no potential difference will exist between individual devices.

Posted by Industrial-Manufacturing at 03:13 AM | Comments (0)

Theramedix Announces a Breakthrough in Enzyme Technology

Exciting news in the enzyme industry. Theramedix is preparing for its launch to health care practitioners in a couple of weeks and has given the world a sneak preview of what's to come. They have unveiled Thera-blend, a new sophisticated technology that addresses the varying pH levels of the body, guaranteeing higher activity and effectiveness.

San Francisco, CA (PRWEB) April 20, 2022 -- Theramedix announced today that health care practitioners will now have access to an enzyme product line that addresses the varying pH levels of the body and specifically the GI Tract. Since the human body presents varying pH levels in the GI tract from pH2-pH 8 (2 –acidic in stomach and 8 –alkaline in small intestine), enzyme formulations should be active in these environments to be considered effective. To address this issue, the company has developed a proprietary Thera-blend™ system for the top 4 categories of enzymes: protease, lipase, amylase and cellulase.

This means that through Thera-Blend technology each of these categories are represented by multiple enzymes, guaranteeing higher activity and natural integrity of each formula. For example, there are four different proteases in the protease Thera-blend (protease is the enzyme that digests protein). The Thera-blended proteases are formulated specifically to deliver efficacy at the entire pH range found in the body. The goal of Theramedix in offering this sophisticated technology is to provide a plant based enzyme line with the highest potency available to the Health Care Professional market.

“Enzymes can provide many health benefits, but the benefits are only as effective as the delivery system. Why formulate something that does not work optimally in the body?” said Kalyna Hanover, Director of Theramedix. “The Thera-blend technology is a true innovation in that it offers genuine functional benefits. Health care professionals no longer have to question whether a particular enzyme is working at various pH levels throughout the digestive system. We have optimized enzyme activity in a wider pH range, while continuing to focus on efficacy.“

“As a significant growth driver at Theramedix, our enzyme research has received our full attention and focus,” said Tom Bohager, CEO of the company. “Innovation has driven our novel Thera-blend technology, and placed our line of products at the forefront of the enzyme category. You would be hard pressed to find another company with such commitment to enzyme therapy.” Unlike most of their competitors, Theramedix does not make vitamin supplements. The company specializes in only enzyme formulations, which range in benefit from enhanced absorption of nutrients to systemic immune support. The new line of enzymes will be widely available in mid-May. All Theramedix products are 100% vegan and vegetarian without any fillers. In addition, each batch is third-party tested for efficacy and label standardization.

Theramedix, a subsidiary of Enzymedica, formulates a premiere line of plant based, pharmaceutical grade enzymes to health care professionals. Theramedix is based in San Francisco, California. The distribution facility is in Venice, Florida. Log onto www.theramedix.net for more information. For media inquires call Constance St. John, The St. John Group, 415-454-2243.

Posted by Industrial-Manufacturing at 03:12 AM | Comments (0)

April 19, 2022

Suffering From Athritis Pain? "Arthritis is the Easiest Disease to Cure" Words That Came From A Miracle Worker Doctor

Is it Possible To Cure Athritis Pain? Then read Margie Garisson's new and revolutionary book entitled "I Cured My Arthritis You Can Too". She suffered athritis since 28 yrs. old and carried it for 43 years, but today she's living a full pain free life!

(PRWEB) April 19, 2022 -- Are you suffering from athritis pain? with the usual sleeples nights and the burden of pain when doing everyday activities? Then I'm here to help you. Hi! my name is Jed Baguio and I would like to whole-heartedly recommend that you visit my partner site http://jedbaguio.arthritis.hop.clickbank.net .In here you will be amazed and astonished of how we can help you cure you're athritis pain Naturally.


This may be a glimmer of hope for all the suffering victim of athritis pain. Our author perfectly understands how it feels to have the pain, the burden and the hopelesness feel of having the athritis disease. How can she understand you may ask? Because she's an athritis victim herself. Inficted with the dreaded disease since she was 28 yrs. old and carried it for 43 years. But her life now is moving in a differnt beat. The beat of living a happy and pain free full life. She's also in a crusade with her all natural athritis treatment to help other athritis victim to, not only alleviate, but cure thier athritis pain. Let's listen to one of her students, Dorothy P. DesMoines from Iowa "I bought your book in November, 1992, I lived by it to the letter. Within two weeks I was off of prescription drugs costing $100.00 per month. Six months later by May of 1993 I had lost 65 pounds. Your book brought me a miracle! I have been pain free since November, 1992." There you have it, words from a forever gratefull patient.

That's why I encourage you to visit the site without delay. You too can live an Athrits Pain free life!
http://jedbaguio.arthritis.hop.clickbank.net

Jed Baguio
Scouring the Net To Help People!

Posted by Industrial-Manufacturing at 03:50 AM | Comments (0)

RxTrocar Ltd Engages Madison Keats™ to Assist in Biotechnology Partner Development

The life sciences investment firm will aid the medical product company in commercialization.

Punta Gorda, FL (PRWEB via PR Web Direct) April 18, 2022 -- RxTrocar Ltd, a biotechnology and medical product company, announced today that it has engaged the life sciences investment banking firm of Madison Keats to assist in evaluating development and commercialization partners for the company. Efforts will be centered on the identification of a development and commercialization partner for the family of proprietary drug delivery trocars and accessories.

"We have engaged Madison Keats due to their specialization in the Global Life Sciences arena and their ability to both evaluate our technology portfolio and assist us in maximizing the value of that portfolio," stated Dr. Stephen Moenning, CEO of RxTrocar. "Working with a life science investment banking firm of this caliber will increase our exposure and assist us in maximizing corporate value."

"Madison Keats specializes in the life sciences area and understands the value of RxTrocar's business model and technology portfolio," stated Jim Zamer, Managing Director at Madison Keats. Robert Capaldo, also Managing Director at Madison Keats added, "Madison Keats builds and maintains alliances with an exclusive clientele that includes several multinational pharmaceutical, biotech, and medical device companies."

RxTrocar has designed four improved versions of the standard trocar for use in every laparoscopic surgery procedure. The company has also developed two "universal" trocar accessories which can be added onto any trocar and used in laparoscopic procedures. As a combination device, much like drug eluting cardiac stents, this proprietary technology provides several benefits over the current trocar technology, including:

1) The RxTrocar™ provides needle-less drug delivery technology, therefore eliminating the problem of needle sticks during its use, establishing a new standard of trocar care.
2) Medication is infused at the port site in a 360º fashion, to just the right depth necessary.
3) RxTrocar™ engineering controls incorporated onto a standard trocar will work for the wide spectrum of patients from pediatric to morbidly obese, thereby reducing redundant inventory.
4) A number of medications and/or treatments can be infused through the RxTrocar™, matching up with a number of laparoscopic procedures.
5) With its strong intellectual property, RxTrocar Ltd is considered the worldwide leader in drug delivery trocar technology.
6) RxTrocar has an immediate product with a 510(k) and two additional generations of drug delivery trocars along with two accessories waiting to be manufactured.

It is widely felt that conversion of the current commodity trocar with RxTrocar engineering controls will create a novel product with a new market. In addition to its clear clinical benefits and its regulatory/governmental advantage over current technology, the RxTrocar has received 510(K) clearance from the FDA. An earlier prototype of the RxTrocar received the "2002 Innovation of the Year Award" from the Society of Laparoscopic and Endoscopic Surgeons.

About Madison Keats, LLC
Madison Keats is a life science investment bank. The firm provides advisory services and focuses on orchestrating technology licensing, creative financing, and mergers and acquisitions. Madison Keats works exclusively within the life sciences industry. Headquartered in Charlotte, North Carolina, the firm is strategically situated in the second largest banking center in the U.S. and within close proximity to Research Triangle Park in North Carolina. For additional information, please visit www.madisonkeats.com.

About RxTrocar Inc.
In 1998, Dr. Stephen Moenning incorporated CA Guard, a company based on a medical product called a Port Site Protector. This Protector was designed for use with cannula and trocar devices for general laparoscopic procedures. Although that device has since given way to more sophisticated technologies, it was the beginning of the development of the current device being offered: the RxTrocar™, an irrigated trocar with engineered controls for medication delivery. The name CA Guard was changed to RxTrocar last year to better reflect the company’s emerging biotechnology growth. For additional information, please visit www.rxtrocar.com.

Media Contact:
Jim Zamer
Managing Director
Madison Keats, LLC
704.377.4121
e-mail protected from spam bots
www.madisonkeats.com

Posted by Industrial-Manufacturing at 03:49 AM | Comments (0)

WaveScribe International Corp in Negotiations With International Transcription Providers

WaveScribe International Corp. announced that since the initial sales campaign of the WaveScribe Platform to transcription service providers, it has entered into negotiations with several International Transcription Providers regarding the licensing and deployment of WaveScribe for their business model.

Las Vegas, NV (PRWEB via PR Web Direct) April 18, 2022 -- WaveScribe International Corp. (OTC: WSBL.PK), makers of the Web-based transcription software, WaveScribe, announced that since the initial sales campaign of the WaveScribe Platform to transcription service providers, it has entered into negotiations with several International Transcription Providers regarding the licensing and deployment of WaveScribe for their business model. Each transcription provider will be able to offer a wide variety of services to their customers by utilizing the WaveScribe platform. The features with these services include batch printing, audit trails, version control, and dictation services. Time and distance are not a factor for users of the WaveScribe platform, since dictation can be accessed, work performed, and returned to the customer 24 hours a day.

WaveScribe has identified some major impact areas for these special-need customers including significant licensing fee savings, HIPAA support and maintenance, technology enhancement, and initial capital outlay reduction.

About WaveScribe:
WaveScribe International Corporation is a national and international dictation and transcription product and service solutions provider for the document production / transcription industry. WaveScribe has several divisions to address industry-specific demands for such specialties as Healthcare, Med-Legal, Education and Entertainment.

Be sure to visit the company at www.wavescribe.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements, other than the statements of historical facts, contained in this release which are not historical facts may be deemed to contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the Company's products and services, the availability to the Company of adequate financing to support its anticipated activities, the ability of the Company to generate cash flow from operations and the ability of the Company to manage its operations.

Media Contact:
Cris Bahar
702-435-9283

Posted by Industrial-Manufacturing at 03:49 AM | Comments (0)

Former FDA Regional Director Joins Medical Device Contract Design Company

Summa Design, a contract design and development company focused on the medical device industry, announced today that Dudley Harris, a former Regional Director for the FDA, has joined Summa Design as Director of Regulatory Affairs and Quality Systems.

Montrose, CO (PRWEB) April 18, 2022 -- Summa Design, a contract design and development company focused on the medical device industry, announced today that Dudley Harris, a former Regional Director for the FDA, has joined Summa Design as Director of Regulatory Affairs and Quality Systems.


Mr. Harris will be working with Summa Design’s client companies offering services ranging from FDA and international regulatory compliance audits to 510(k) submission coauthoring and review. He will serve in an advisory role on most projects to ensure a smooth transition of the client’s product through the FDA approval process.

Jon Ferris, President & CEO of Summa Design, stated, “As a leader in the medical device outsourcing industry, we are constantly striving to be responsive to the needs of our clients and reduce overall time-to-market. We are excited that Dudley’s skills and experience complement our existing expertise so well.” Mr. Ferris went on to explain, “We have a team of senior-level engineers and managers and have developed an efficient engineering process to get products realized quickly. We can now carry that efficiency well beyond design and development into the regulatory approval process.” He added, “Having a former Regional Director on staff to share his 30 years of insider’s knowledge of the FDA will benefit virtually all of our clients. Our reputation as a first-class outsourcing firm is strengthened today as we welcome him to our team. Our broad range of services continues to clearly differentiate us from the competition.”

The Company
Summa Design is a global, privately-held, medical device contract design company based in Colorado. Their client list includes Fortune 500 medical device companies, as well as small start-ups. Summa Design provides an unparalleled range of services in the industry, including engineering design and development services, marketing, sales, distribution, and FDA and international regulatory consulting. Summa Design was the first contract design firm to offer an industry-leading “VC Partner Program©”, which promotes relationships with venture capital companies and allows Summa Design to introduce start-up clients to funding sources. For more information, please visit www.summa-design.com.

Posted by Industrial-Manufacturing at 03:48 AM | Comments (0)

Hot Pepper Nasal Spray Could be The Answer To Allergies & Rhinitis

More than 22 million Americans suffer from allergic Rhinitis, most commonly referred to as “hay fever”. Every spring through autumn, patients pop pills, and snort nasal sprays with dangerous side effects and no real relief. Finally science is beginning to pin down the causes and treatments for chronic allergies, and according to many, the answer for relief may be old fashioned “Hot Peppers”.

Albany, NY (PRWEB) April 18, 2022 -- More than 22 million Americans suffer from allergic rhinitis, most commonly referred to as old fashion “Hay Fever”. For the average patient, Hay Fever is simply the laymen’s way of describing what is regarded as general allergies. Chronic cases can include any combination of symptoms including stuffy nose, watery eyes, fatigue, and worst of all -- headaches. General Allergy symptoms can be caused by a variety of triggers including pollen, mold, fresh cut grass and blooming spring flowers.

Most allergy sufferers respond to more than one environmental trigger making allergy season considerably longer than most people realize. For instance, a person who reacts adversely to spring flowers and low pollen counts may also react to high pollen counts in late summer. The average American allergy patient will experience a variety of symptoms from early April through late September – with the severity of those symptoms fluctuating throughout. As pollen counts change and humidity levels increase, many patients experience more severe symptoms. In addition, temperatures and wind speeds are also important factors that effect allergy sufferers. Basically it all adds up to chronic sufferers being forced to continue long term usage of Over The Counter (OTC) and Prescription allergy medications with no real end in sight, and no true relief either.

Though many of the most popular allergy relief products have been on the market for years, it is widely believed by physicians that long term use of these pills and nasal sprays can be dangerous and possibly addictive. In recent years, the medical industry has attempted to steer patients away from artificially synthesized drugs, and toward more natural methods. Dehumidifiers, Hepafilters, Saline Sprays and Nasal Irrigators have all become highly recommended by doctors, but now there’s an “all natural” nasal spray that may prove to be the answer to nearly every allergy sufferer’s prayers.

It’s the world’s first hot pepper nasal spray known as “Sinus Buster”. Within one year, this strange product has built an impeccable reputation with more than one thousand physicians around the world. Sinus Buster’s main active ingredient is hot pepper extract – particularly Capsaicin, the natural chemical that dictates the hotness of hot peppers. According to officials at SiCap Industries, makers of Sinus Buster, the effectiveness of their product relies on more than just the capsaicin.

“In the pharmaceutical industry they sometimes have a tough time thinking out of the box. With them everything relies on one main active ingredient. It’s all about synthesized drugs that are far removed from their natural compounds. That’s because they can get a lot more money for something that’s been synthesized so it can become a patented drug. Big Pharma avoids natural medicine because the profit is so much lower, but they use the best aspects of natural cures to design their drugs. Yes capsaicin is the main active ingredient in Sinus Buster, but the eucalyptus and rosemary are equally important. We’ve spent years honing this formula to get the right combination of all natural ingredients. After all this is the only all natural capsaicin based nasal spray available and it works like a charm,” says Wayne Perry, President of SiCap Industries.

Sinus Buster does have one heck of a reputation for relieving chronic sinus conditions and chronic headaches. It also has one heck of a bite when you first use it. Sinus Buster wakes you up faster than a strong cup of morning java. There’s no doubt this formula instantly relieves nasal congestion, but it also has a cumulative effect on blocking allergy triggers such as pollen. Most chronic allergy sufferers who use Sinus Buster claim near complete relief within two weeks of use, and complete relief within a month. Beyond the first month, most allergy patients reduce usage to an “as needed” regimen to aid in the blocking of allergy triggers thus preventing chronic symptoms altogether.

“The whole secret to Sinus Buster is it works for most everyone. While some people need to use it regularly to combat severe chronic allergies, many other people may only need to use it once in a while like on days when the pollen count is high. This formula really is the answer to every allergy sufferer’s prayers. We’re talking instant symptom relief for most users,” Perry explains.

Sinus Buster has recently grabbed the attention of some major medical researchers due to the overwhelming body of anecdotal evidence both from patients and physicians. SiCap industries is presently involved in several clinical trials concerning various sinus and headache treatments. A new study about to begin in the United States is concentrating on Sinus Buster’s effectiveness for relieving allergic Rhinitis symptoms. Many doctors are already recommending Sinus Buster as a replacement for OTC sprays and intranasal steroids -- namely because it’s effective and safe for extended use.

“The key to fighting allergies over the long term is that patients have to continue treatment basically forever. If you have spring allergies or summer allergies or whatever, you will always have symptoms during those periods. So you need something that can relieve the symptoms and prevent them at the same time. You need something you can take as often as you may need depending on the allergy triggers you’re facing. You need something with no added chemicals and no artificial crap. Sinus Buster is completely natural and it’s designed to be used as often or as little as necessary. So it fits everyone. All the ingredients are totally natural food grade ingredients, and it’s even considered safe for pregnant women. No other nasal spray can say that,” adds Perry.

Sinus Buster can be purchased on the web and in select retailers throughout North America. This formula is available in the original stream spray bottle (10.99), and the newer metered dose bottle ($15.99). Doctors recommend the metered dose version for treating allergies and chronic sinus conditions. Both bottles work against headaches of various types although the stream sprayer may prove better for acute cluster headache attacks.

Information about Sinus Buster is everywhere – from WebMD to MSN. You can even find it on Ebay, but the best way to find out more is to visit the company website at (www.sinusbuster.com). You can find links to local retailers there, and an online store that offers SiCap natural health products. Samples and info kits are also available for qualified media and medical personnel upon request.

Posted by Industrial-Manufacturing at 03:47 AM | Comments (0)

Autism and Asperger's Audio CD Spreads Awareness & Hope

The Audio CD, "Living In the Spectrum: Autism & Asperger's", offers an easy, practical way to learn about Autism and Asperger Syndrome in an engaging and artfully produced presentation. This unique CD not only educates, but inspires hope with it's optimistic approach. During April which is "Autism Awareness" month, a portion of the proceeds from the CD sales will be donated to various Autism organizations.

Royal Oak, MI (PRWEB) April 18, 2022 -- Being that April is "Autism Awareness" month, and with 1 in 166 children now being diagnosed with Autism or it’s close relative, Asperger Syndrome, MindscapeProductions.com are donating a portion of the proceeds from the sale of their audio CD about Autism and Asperger Syndrome to various Autism organizations to help raise awareness, acceptance and understanding about the conditions.


The CD, entitled “Living In The Spectrum: Autism & Asperger’s” is filled with valuable nuggets of insight from researchers, parents and individuals who have Autism or Asperger’s. It features captivating music, poetry and intriguing interviews.

“Living In The Spectrum” is an ideal primer for parents, relatives, school districts, teachers, employers, doctors or anyone wanting to learn about Autism and Asperger's. The 55-minute CD delivers a captivating introduction to the subject matter. Co-producer, Lecia Macryn states, “What makes this presentation unique is that it not only educates people about Autism and Asperger's and presents the facts, but also puts a positive perspective on it. It offers hope, encouragement and highlights the gifts those in the autism spectrum bring us. Plus, because it’s an audio CD, people who don’t have much time on their hands can listen to it while driving, on the treadmill or working on their computer.”

Liane Holliday Willey, Ed.D., Senior Editor of "Autism Spectrum Quarterly" magazine (www.ASQuarterly.com) calls it, “An inspired masterpiece. A finer multi-media production exploring and explaining Autism and Asperger Syndrome is, to my knowledge, simply not available. This is one powerful production.”

The Audio CD, “Living In The Spectrum – Autism & Asperger’s”, ISBN# 0976576007 is available for $16.95 online at http://www.MindscapeProductions.com or on www.Amazon.com

During April, which is "Autism Awareness" month, a portion of the proceeds from the CD will benefit various Autism organizations.

For more information or to request a press/media review copy, contact Lecia Macryn at Mindscape Productions: (248) 288-2242.

Posted by Industrial-Manufacturing at 03:46 AM | Comments (0)

April 17, 2022

Stop Smoking Laser Clinic Frees Teens from Addiction

Freedom Laser Therapy discounts their quit smoking laser treatment to help young adults

(PRWEB) April 15, 2022 -- An innovative low-level laser quit smoking treatment used in Europe and Canada over the past 30 years is now available in the United States. Freedom Laser Therapy, a leading practioner of laser therapy treatment focuses on the physical, psychological, and detoxification of breaking a smoker’s nicotine addiction. Freedom clients are continually referring others smokers to the clinic, because of the simplicity of quitting using the treatment.


Craig Nabat, President of Freedom Laser Therapy, wants young adults to have the same ease of quitting smoking as Freedom’s adult clients. Nabat initiated a company wide policy that young adults showing proof of being under 21 years old can receive the $399 laser therapy treatment for only $99.

Nabat is passionate about his company's mission of freeing the world from nicotine addiction, so much that he is now focusing on the youth of America. Presently, 22% of high school students are smokers. According to tobacco research reports the industry is earning over 1.8 billion from underage sales of cigarettes to America’s youth.

According to the American Lung Association 90% of all smokers begin smoking before the age of 21. Even more alarming is that 3,000 new teenagers per day are daily experimenting with smoking; and addiction can occur within as little as two weeks. Some reasons why kids usually light up are as followed: To fit in, to be part of a group, to look cool, pure experimentation, they have friends who smoke, to be rebellious, to look older, a family member smokes, influenced by tobacco advertising geared towards them, or emulating a favorite celebrity who is seen smoking in a movie.

When young people begin smoking, they are not truly aware of the seriousness of their experimentation. Unfortunately young adults do not realize how easy it is to become addicted to nicotine, nor do they look at the health risks associated, such as cancer, emphysema and even death. In addition, young smokers cannot conceptualize the approximate $1,800 a year expense that they will encounter when they become addicted to cigarettes.

Nabat, a former smoker himself says, "Smoking education awareness campaigns for youths is only half the battle. Young smokers need to have an effective resource available to break their physical addiction to nicotine.” “Laser therapy is the easiest solution to painlessly break a smoker’s nicotine addiction, which may encourage young adults and teens to quit smoking sooner.”

Freedom Laser Therapy
720 Wilshire Blvd.
Third Floor
Santa Monica, CA 90401
310-458-5558 tel Santa Monica, CA
248-547-5600 tel Royal Oak, MI
www.freedomlasertherapy.com

Posted by Industrial-Manufacturing at 11:38 PM | Comments (0)

April 14, 2022

Latest Non Invasive, Non Surgical Skin Tightening Using Latest Infrared Light Based Technology - Titan

The Titan Procedure is a safe, non-surgical process that uses an infrared light source to tighten skin and reverse the signs of aging. The Titan heats the dermis to cause collagen contraction while preserving the epidermis through continuous cooling. In addition, Titan can stimulate long-term collagen rebuilding that leaves patients with younger looking skin. Excellent long term results are Obtained for those who wants to tighten their skin, Correct asymetry, eye brow lifting Etc.

(PRWEB) April 14, 2022 -- Dr. Mahaveer Mehta Medical Center, Dubai, United Arab Emirates is one of the first in this part of world to have latest safe light based solution for aging skin. The Titan Procedure treats lax and redundant skin throughout the body including the abdomen, thighs and underarms and is also used to tone, lift and tighten skin on the face and neck.

The Titan Procedure:
Safe, comfortable, non-surgical treats lax and redundant skin throughout the body - can stimulate long-term collagen rebuilding. Although non-ablative radiofrequency can produce skin tightening, significant pain from its application limits the patient population of possible candidates to those with sufficiently high pain tolerance and those willing to undergo significant pain during the procedure. Topical anesthetics are only modestly helpful in lessening this pain. Injectable anesthetics are not recommended due to the possibility of altering the local impedance of tissues, causing an unwanted burn. Producing painless skin tightening via non-ablative radiofrequency is not yet possible unless the patient is deeply sedated or receives systemic anesthesia. A new non-ablative medical device: Titan (Cutera, Inc. Brisbane, CA) has been successful in producing skin contraction leading to lifting of eyebrows and/or improvement of lower face and neck skin laxity. This device has also been used successfully in other body areas such as abdomen, arms and thighs. Immediate changes have been noticed in the vast majority of patients. The degree of pain is quite low, to the point of needing no anesthesia. Patient satisfaction has been remarkable. There is no down time and no incisions or scars either. Additionally, the patient will look like himself after the procedure. The results have a remarkable natural look which, plastic surgery rarely can match. The patient will look less tired, with a freshened look. The skin contraction achieved is in the order of 1 to 3 millimeters. It may not sound dramatic, but the changes induced by such contraction are perceptible and significant when it comes to eyebrow lifting or fading of the naso-labial fold. Follow-up visits show that the improvement has been maintained and even increased. In fact, the degree of improvement has not diminished during follow-up in any of our patients. Post operative patients can go back to their normal activities right away. Erythema is sometimes seen in patients with skin type I, but it usually fades within an hour. Occasionally blisters develop. They are usually isolated single vesicles, probably the result of incomplete skin contact with the cooling sapphire crystal during pulses. When they do happen, the patient should avoid any picking or other manipulation. These vesicles usually resolve without marks. The new Titan system from Cutera has a similar thermal profile in ex-vivo skin specimens detected by thermal photography. It also has significant advantages over non-ablative radiofrequency. For one thing it has a multi-second pulse which provides a gentle and sustained skin heating that clinically is much less painful and has similar if not better clinical results as compared to Thermage. The safety profile is very good with adequate physician training and the results are as satisfactory as can be expected with any modern technology in this field.

You can see Cutera website for more info at
http://www.cutera.com/prodapps/titan_intl.asp?view=photos

Posted by Industrial-Manufacturing at 04:45 AM | Comments (0)

Localization World Scheduled May 31 – June 2, 2005, in Bonn, Germany

Localization World — a conference devoted to localization — will be held on May 31 – June 2, 2005, in Bonn, Germany. The three-day event consists of one day of preconference workshops and two days of conference sessions, exhibitions and networking.

(PRWEB) April 14, 2022 -- What does the EU expansion mean for your company and products? How can you market to different cultures and languages?

As business people seek new markets for their products and members of the public sector strive to serve multiple publics, it becomes critical to properly adapt products and services to specific languages and foreign cultures. The process of adapting a product, service or software to a language or culture so that it seems native is called localization.

Companies that want to know more about localization — and how to do it right — will have the opportunity to learn at Localization World, May 31 – June 2, 2005, in Bonn, Germany. The three-day event consists of one day of preconference workshops and roundtables, and two days of conference sessions, exhibitions and networking.

“Experts from around the world will help attendees learn about management and technical issues,” says Donna Parrish, publisher of the magazine MultiLingual Computing & Technology and one of the organizers of Localization World.

“Since the European Union was enlarged from 15 to 25 countries,” Parrish said, “the number of official languages increased from 11 to 20 which will affect many businesses and institutions. “We’ve designed this conference to appeal to localization professionals and managers, both on the customer side and service side to help them deal with these challenges.”

The theme of the conference is "Double the Language Challenge," with three concurrent tracks and presentations by professionals in the world of global business and technology. Localization World Bonn 2005 will have a special emphasis on marketing communications (marcom), the public sector and the European Union. Sessions and roundtables will also address translation automation, the needs of the automotive industry, medical device manufacturing and software publishing.

On June 1, top executives from Bowne, Microsoft, SDL, SAP and Oracle will lead a keynote panel discussion on the new challenges in Europe. On June 2, author David Arnold will make a keynote presentation on “Global Power Brands.”

Localization is a vital function around the world. Representatives from 35 countries attended the last event in Bonn. Localization World Bonn is produced by MultiLingual Computing, Inc., and The Localization Institute in cooperation with The Globalization and Localization Association (GALA).

Advance registration discounts are available through April 15. More information about the event can be found at http://www.localizationworld.com

Posted by Industrial-Manufacturing at 04:44 AM | Comments (0)

April 13, 2022

WaveScribe International Corp's Industrial Medicine Division Announces Expected Increase in Revenue

Las Vegas, NV (PRWEB via PR Web Direct) April 13, 2022 -- The Industrial Medicine division of WaveScribe International Corp (OTC: WSBL.PK) has been informed it will receive an increased workload from one of its largest clients. Due to our clients company policy, we are unable to provide the name of this specific client however, the client, (a top 10 California HMO based on revenue and number of participants), has had discussions with WaveScribe and Division Principals about increasing their outsourced workload. The workload currently outsourced by this HMO could significantly increase due to the client's substantial growth, streamlining and consolidation of operations. According to client management, the WaveScribe platform has become an integral ingredient of their multiple facilities. This should equate to an approximate 15% increase in quarterly revenues just from this client. The industrial Medicine division, formed fall 2004, has been in discussions with its current clients on the topic of increased Company utilization and expansion of services. The Company also anticipates signing several prospective clients in the near-term.

Cris Bahar, CEO of WaveScribe International states "We’ve diligently worked to create a product that, when used properly, can be utilized to create a seamless bond between care providers, myriad departments and multiple facilities for their document production and workflow needs. Specifically, for the time-sensitive industrial medicine industry, the WaveScribe platform can become the dynamic link for clinical, legal and patient resources to create and maintain accurate records of examinations, studies, evaluations and conclusions."

About WaveScribe
WaveScribe International Corporation is a national and international dictation and transcription product and service solutions provider for the document production / transcription industry. WaveScribe has several divisions to address industry-specific demands for such specialties as Healthcare, Med-Legal, Education and Entertainment.

WaveScribe offers the first web-based transcription software that was designed, developed, and deployed by transcriptionists. Documents created through WaveScribe have a 128-bit security encryption, HIPPA and Privacy Law compliance. Access to a medical or legal transcribed document for editing, reprints, updates, 24 hours a day in a simplified and cost-effective manner to handle the task of document control is now available. The WaveScribe platform requires no software to purchase, and installation on to a specific PC is not needed. The transcriptionist utilizing the platform can use several methods to create documents such as uploading existing documents and/or formats while maintaining the traditional methods of transcription such as analog tapes, digital tapes, handheld devices, phone in rerecorded or pushed and even computer generated methods. In addition, future advances include speech-to-text and net/web (documents created on a private network automatically stored and accessible on the internet platform).

Be sure to visit the company at www.wavescribe.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements, other than the statements of historical facts, contained in this release which are not historical facts may be deemed to contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the Company's products and services, the availability to the Company of adequate financing to support its anticipated activities, the ability of the Company to generate cash flow from operations and the ability of the Company to manage its operations.

Media Contact:
Cris Bahar
702-435-9283

Posted by Industrial-Manufacturing at 11:31 PM | Comments (0)

The Skinny on the Popularity of Natural Breast Enhancement and the Companies that Sell Those Products

Real Health Method is a revolutionary company which specializes in providing ‘real’ solutions and alternatives for health-related, cosmetic, and several other everyday issues. This press release introduces the first of the ‘Real Health’ series of e-books available in soft and hard copies. Subject- Natural Breast Enhancement

(PRWEB) April 13, 2022 -- What about natural breast enhancement?
The past decade has seen a significant rise and notice in the validity of herbal treatment for ailments and cosmetic improvements notwithstanding the area of natural breast enhancement. Most of the current breast enhancement products promise anywhere to ‘definite improvement in firmness’ to ‘within 1-3 months time’ a gain of at least one cup. All use some type of phyto-estrogenic derivative in varying ratios and other fillers. Although, the range of raw materials used (commonly red clover, fenugreek, fennel, and others) have shown historically, tribally, and scientifically to stimulate breast growth, it may not be valid for most of their costumers.

What is not as widely heralded is the growing disappointment of the costumers of these commercial breast enlargement products. Comsumeraffars.com reports on 7-12-04 of the company Herbal Breast being sued by the state of Washington., “The consumer protection suit filed in King County Superior Court accuses Nature’s Advantage LLC, and its Marysville, WA, owner, Vaughn Wolfe, of making numerous unsubstantiated claims for the breast-enhancement products on two websites …” Another, headline reads “Small Breast Solutions' Agrees To Halt Sales” as this company sold a breast enhancement mix which largely failed to live up to its promises also. The list is beginning to grow. Still, however the science of breast enhancement is very real.

Breast growth is stimulated by a sacred balance of hormones such as the precursor hormone progesterone and its derivatives estrogen and testosterone. Other factors included Human Growth and I-GHF hormones which assist with timing of the release of these hormones. Prolactin and progesterone work to promote glandular growth. Prolactin and estrogen work synergistically to allow fat storage, mainly in the breasts. Estrogen alone promotes fat storage. In women, the level of this hormone is generally higher as compared to men. It provides to reason how women are generally more curvaceous. The latter are all observations scientifically proven. It’s also been proven that some herbs and food sources simulate the estrogen, testosterone, and progesterone hormones in the human body. The plant source of estrogen is referred to as phyto-estrogen, of testosterone as phyto-androgen, and of progesterone as phyto-progesterone. Some foods rich in phyto-estrogens include thyme, turmeric, fenugreek, licorice, and many, many others. Upon some thought, Italians have diets rich in fennel, licorice, and turmeric and certainly have their share of busty females, but we digress.

In the United States, the range of diets include many variations of estrogenic foods, however, all here are definitely not busty. The great news is that it is possible to determine the correct hormonal sources to stimulate your own breast growth.

The Only Natural Breast Enlargement Solution
The key to natural breast enlargement success is correctly simulating the woman’s system with the correct natural breast enhancing herbs. Where the current commercial natural breast enhancement products generally fail is that their formulation does not account of the individual genetic make-up of each woman. Each and every human being is unique. Therefore you can not give the same item, same formulation to any one and expect the same results. Hence why all pharmaceuticals list the side effects observed for the use of that product. To eliminate the chance of side effects, scientists would need to test the 5+ billion people of this earth in controlled studies- an impossible feat. This is where the e-book product offered on Real Health Method for natural breast enlargement comes of significant use.

‘Real Breasts, Real Health’ uses a special innate talent that all humans have to help a woman pick the herbs, vitamins, minerals, foods, diet to provide the perfect conditions for breast growth. The book also details common mistakes during this kind of regimen and tips and motivation for staying on track. Additionally, those with any concerns for breast cancer by using products will learn their how prone they are and what to use to not only avoid increasing those risks but grow breasts also.

The age range of successful customers is from 18-55, menstrual and menopausal. Testimonies include reduction of PMS and HRT symptoms in the process. The regimens of the younger set are more filled with vitamins and a few herbs taking from 2-4 months to grow a full cup, while those closer to menopause or in it full-blown have a more weighty program including usually including the use of progesterone cream, BE herbs, vitamins, and minerals; they also average from 4-8 months for the first cup. Both groups’ subsequent cups were faster. After a year; the younger set- 3+ cups, older set: 2+ cups. Starting range is AAA to saggy C’s. The success rate of 1+ cup of growth for those who master the technique is 93.8% and improving. Incredibly, the costs of these regimens have ranged from $200- $1000 for permanent growth.

The concept is simple, and results are very real. No empty promises or chances of lawsuits here. So, for those whom breast surgery is not a viable option and they really care about their health and are open to an exciting new method, this site is worth the visit. With a 90-day, 100% money-back refund guarantee, how can investing $15 for the book’s purchase lead you wrong? Folks throw away more money on four Starbuck’s cups of coffee in a week.

Upcoming books include a beauty solution book for the riddance of acne topically and what real diet modifications needed to eliminate them forever, how to alleviate all symptoms of your herpes simplex I and II, fungus nail treatment solutions, and many more ideas; these solutions will be in the ‘Real Beauty, Real Health’ release. Other subjects/e-books in progress include weight-loss (Real Weight-loss, Real Health), how to permanently treat MS, Alzheimer’s and other chronic issues (Real Relief, Real Health), erectile dysfunction, vaginal dryness (Real Intimacy, Real Health), and an HRT book (Real HRT, Real Health). Check in often for release updates and progress.

Posted by Industrial-Manufacturing at 11:29 PM | Comments (0)

Sinus Problems: Is There an Answer?

Just Buy Online offer effective short-term relief and long-term preventative solutions to Chronic Sinusitis and other conditions.

(PRWEB) April 13, 2022 -- Sinus Problems: Is there an answer?

Sinus related problems are on the increase. There’s no doubt about it.

From chronic sinusitis to allergic rhinitis, sinus-related migraines to catarrh, there are many variations on the specific conditions experienced by sufferers.

Sinusitis in particular is very common, and if left untreated it can become chronic. Sinusitis is caused by bacterial infections in the nasal passages, which spreads into the sinus cavities. To combat the infection, blood flow to the sinuses is increased, which causes inflammation and swelling. The swollen sinuses then block the small hole through which mucus is drained, causing pressure to build in the cavities behind the cheekbones and forehead, until it can somehow be released. Headaches and uncomfortable sleep are just some of the effects of sinusitis on everyday life.

Sinusitis now affects millions of people worldwide. Research conducted in the UK showed that 44% of UK households have at least one sufferer of sinusitis and related sinus problems. It also shows that only 29% of them seek treatment of these conditions. In the US, health care experts are estimating that more than 30 million Americans are affected by sinusitis every year, with over 25 million cases of Chronic Sinusitis being recorded by the Center for Disease Control and Prevention. This has led to millions being spent on treatments that promise to relieve or prevent these problems.

On top of this, maybe 75% of asthma sufferers also contract sinusitis. Shocked by the numbers?

There are many different treatments available now, to people with chronic or recurring conditions. Some are advised by their medical professionals to have surgery, others take harmful antibiotics, which upset the natural balance of the immune system. Some retailers offer “natural solutions” such as oils or candles to relieve the symptoms of sinusitis and related conditions.

But no matter which way people choose to try and relieve their sinus condition, one thing is certain. We shouldn’t have to put up with the pain of chronic conditions like sinusitis.

The American Academy of Allergy, Asthma and Immunology says, "Chronic sinusitis, lasting more than eight to 12 weeks, can significantly affect worker productivity and school performance on an individual level."
So at work, school and home our performance and energy levels are greatly lowered by these conditions.

Fortunately, Just Buy Online Ltd may have the answer. Their website http://www.JustNaturalStuff.co.uk/, is the sole UK distributor of the #1 selling sinus irrigation system, Hydropulse. The Hydropulse system works by delivering a pulsed flow of saline water to the nasal passages and sinus cavities, flushing out infections, removing scabs from nasal surgery, unblocking noses and sinuses and treating associated conditions such as post-nasal drip, catarrh and halitosis. 37 Independent Ear, Nose and Throat specialists also recommend this highly effective product.

They also sell RinoFlow, a similar system designed to deliver a light saline mist to the nasal cavities instead of water. Both of these high performance, top-of-the-line products are available VAT free, by filling out a VAT exemption form stating your condition. Order them today, and receive them within 3-5 days. Offering fast relief from the symptoms of sinusitis and used long term is a good preventative measure for those with recurring problems.

Forget antibiotics or surgery! Get a sinus irrigation system at JustNaturalStuff.co.uk today and you’ll never look back.

Posted by Industrial-Manufacturing at 11:27 PM | Comments (0)

New Medical ID Jewelry Catalog Now Available

HAH Originals announces the availability of their 2005 Medical ID Jewelry Catalog.

Corvallis, MT (PRWEB) April l3, 2005 -- Many people have health conditions that in the event of a crisis need to be communicated to emergency responders. Unfortunately a large number of these people don’t wear medical id jewelry because they see the existing jewelry as “clunky” and rather unfashionable. But according to Heather Condos, the owner of HAH Originals, “We aim to change that by providing custom engraved medical ID and alert jewelry that people will look forward to wearing.”

Emergency response providers, as well as medical professionals and caregivers, have long recognized the importance of having readily available patient information. HAH Originals’ new twenty-page catalog contains a variety of unique medical ID bracelets and alert jewelry that can be custom engraved with the customer’s medical information and worn on the wrist for immediate availability.

One of the challenges that many parents face is getting their children to wear an alert bracelet. According to one customer, Stephanie Merves from New Jersey whose 12-year-old daughter suffers from diabetes, “My 12-year-old daughter loves them. She immediately put on the Pink Flutterby bracelet and was thrilled with how perfectly it matched her outfit. I never thought she could be so excited about a diabetes medical alert bracelet. She is very much looking forward to wearing the additional bracelet bands she selected.”

Included in the catalog are medical ID and alert products for children and adults that feature swappable bands.

The catalog is free for distribution by health care professionals, physicians, pharmacists. clinics and health care associations.

For further information or to request copies of the catalog, please contact Heather Condos at 1-888-475-6339.

HAH Orignals, LLC is based in Corvallis Montana and sells custom engraved medical ID jewelry online at http://www.hahoriginals.com as well as through mail order and telephone sales. To date, HAH Originals has over 2500 customers worldwide.

Contact Information:
Heather Condos
HAH Originals. LLC
PO BOX 818
Corvallis, MT 59828
1-406-961-5565 or 1-888-475-6339
http://www.hahoriginals.com

Posted by Industrial-Manufacturing at 11:26 PM | Comments (0)

April 12, 2022

Fight Seasonal Allergies Naturally with Xlear Nasal Wash

Xlear Nasal Wash helps wash away dirt and pollutants that trigger allergies

Salt Lake City, UT (PRWEB) April 12, 2022 -- With Spring, comes allergies; and while many allergy sufferers continue to reach for over-the-counter and prescription medications, more people are beginning to turn to Xlear Nasal Wash, an all natural solution that helps to hydrate the nasal passage and provide relief from irritation caused by pollutants, allergens and infections in the nasal passage. Xlear Nasal Wash was developed by Xlear, Inc. and is a natural alternative to antihistamines and prescription steroids, which are the norm for treating allergy symptoms. To date, more than 1 million bottles of Xlear have been sold online at www.xlear.com and through natural products and health food stores across the country.

Xlear Nasal Wash is a patented nasal cleansing solution containing xylitol, a sweetener found in woods, fruits and other natural sources. The all-natural xylitol/saline wash is designed to enhance the body's natural cleansing process by flushing out airborne allergens and pollutants that are inhaled through the nose. As the key ingredient in the nasal wash, xylitol makes it difficult for bacteria to adhere to the nasal tissues while increasing the natural moisture flow process in the nasal passage.

“According to the Asthma and Allergy Foundation of America, allergies are the sixth leading cause of chronic disease in America and make life difficult for more than 50 million children and adults every year,” said Nathan Jones, president of Xlear, Inc. “Xlear Nasal Wash is a drug-free solution that is safe for children and adults and has helped thousands of people across the country make it through tough allergy seasons. While many allergy drugs shut off the body's natural cleansing process, Xlear works by keeping the nasal passage moist and helping the body to wash out potential allergy triggers. Since we introduced Xlear Nasal Wash in 2000, it has continually grown in popularity, providing natural relief for our customers across the country.”

The xylitol in Xlear Nasal Wash helps to break up and inhibit the attachment of bacteria in the nasal passage. Washing the nose with a hyperosmolar solution (draws out moisture), such as Xlear Nasal Wash helps to flush out allergens and irritants that lead to sinus and nasal problems. When not removed from the body, the allergens cause the body's immune system to release histamine and other chemicals. The reaction to the chemicals includes nasal swelling, sneezing, itching, irritations, excess mucous production and sometimes asthma. Xlear Nasal Wash helps flush out the allergens before the irritation starts, providing clearer nasal passages and less dependence on over-the-counter or prescription medications.

Xlear Nasal Wash is available by calling 1-877-599-5327, online at www.xlear.com or from many health and nutritional stores across the country. To find a local store, please visit Xlear’s Retail Store Locator at http://www.xlear.com/locateStore.aspx

About Xlear, Inc.
Founded in 2000, Xlear, Inc. (pronounced “clear”) is recognized as one of the leading manufacturers of xylitol products, and one of the largest importers of xylitol in the United States. Xlear, Inc. is committed to providing consumers with the health benefits of xylitol by manufacturing all-natural, health-enhancing products. Xlear, Inc. offers Xlear®, a patented nasal wash; a complete line of dental health products offered under the SpryTM Dental Defense System brand; and XyloSweet TM, raw xylitol crystals used as a sugar substitute in cooking, baking and general consumption. Xlear, Inc. is a private company with headquarters in Orem, Utah.

Posted by Industrial-Manufacturing at 03:31 AM | Comments (0)

Happiness in a Bottle?

Has the U.S. been tricked into believing prescription pills can cure everything?

(PRWEB) April 12, 2022 -- According to recent drug ads we can cure every ailment – from depression, anxiety, insomnia, hyperactivity, even the change of life. When did Americans become so gullible? Could it be that when the FDA relaxed the rules for television advertising of prescription drugs, we bought this illusion of happiness?

The fact that drug ads soared from $12 million to $1.58 billion in a decade indicates that the direct-to-consumer ads are working. Many patients ask their doctor for a drug by name or self diagnose their symptoms based on what they see on television. When did this dangerous trend turn on us as a society?

The recent murders by Jeff Weise, a sixteen year old a resident of the Red Lake Indian Reservation who killed nine people before killing himself has left the country in shock and wondering whether Prozac, Paxil, Wellbutrin, Lexapro, Zoloft, Xanax, Valium or any drug for ADHD is safe for our children.

We have heard many theories as to the cause – trauma, guns, poverty, goth culture, even video games. And yet, the question many parents are quietly asking is whether the drugs so readily prescribed to our children are increasing the risk of school shootings. Could such a tragedy have been avoided?

These are the questions that are addressed by Label Me Sane, a California organization dedicated to raising awareness regarding the dangers of prescription psychoactive drugs. Since the shootings in Minnesota they have been inundated with requests from parents seeking safe solutions to withdraw their children safely off behavioral drugs. Multitudes of adults have also requested assistance to withdraw from anti-depressants, sleeping pills or anti-anxiety drugs safely and without the withdrawal symptoms so many have suffered.

Recent statistics show that 40-50% of the American public is on anti-depressants. This does not include the use of anti-psychotics, stimulants and anti-anxiety drugs, such as sleeping pills – making the total number of drugged Americans into the tens of millions. What happens when someone tries to withdraw off a behavioral drug?

Many describe the withdrawals as excruciating, terrifying and worse than the depression or anxiety they were trying to treat. This is certainly nothing we want our children to suffer through.

Alesandra Rain, co-founder of Label Me Sane suffered terrifying withdrawals when she tried to stop her antidepressants and anti-anxiety drugs. It forced their organization to seek safe alternatives to withdraw off drugs without the crippling symptoms she suffered. “I don’t want anyone to suffer as I did. There is a solution available to withdraw safely and I encourage everyone to contact us for the information,” states Rain.

Contact www.labelmesane.com for more information.

Posted by Industrial-Manufacturing at 03:30 AM | Comments (0)

April 11, 2022

Hot Peppers Could Be The Cure For Springtime Allergy Woes

Just as people everywhere are opening their windows in search of fresh spring air, Mother Nature is brewing up her annual cocktail of pollen, dust and mold that can be downright hazardous. Welcome to yet another allergy season, but this year science may hold a true breakthrough using an age old remedy.

Albany, NY (PRWEB) April 11, 2022 -- Just on the heels of another long drawn out winter, April kicks off the highly anticipated springtime warm up, but this hopeful month also ushers in the official start of allergy season for most of the country. Just as people everywhere are opening their windows in search of fresh spring air, Mother Nature is brewing up her annual cocktail of pollen, dust and mold that can be downright hazardous.

“I can’t breath once we get into the last week of April and it usually lasts right through June. I get itchy watery eyes and swollen sinuses, and as the weather gets warmer I sometimes get headaches too. My doctor has tested me for certain allergies, but it seems we cannot pin it down. I’m just plain allergic to the combination of whatever is floating around in the air. I really missed being able to open my windows in spring and early summer and enjoy the fresh air, but I just couldn’t deal with the allergies. I was on all kinds of medicines for years, but mostly they just covered up the worst of my symptoms without relieving me of the entire problem. Then last year I found something that finally worked on my allergies and I mean it really worked. Of all things it hot pepper. At first I started drinking tea with cayenne pepper that I read about on the web and it definitely helped alot. Then I found an actual hot pepper nasal spray at a local health food store, and it totally worked on my allergies. Now I can't live without the stuff,” says Tammy Kraft of Baltimore, Maryland.

Tammy is referring to a commercial nasal spray known as Sinus Buster. Billed as the “World’s first & only” hot pepper nasal spray, Sinus Buster has become a lifesaver for thousands of allergy sufferers in the know. The secret is a natural substance found in hot peppers called Capsaicin. This natural chemical is the ingredient that puts the “Hot” in hot peppers. Though clinical studies concerning the effects of capsaicin on allergies are still somewhat obscure, there have been dozens of studies showing this natural heat generator to be highly effective against a wide variety of chronic sinus ailments and most types of headaches. Nonetheless, thousands of allergy sufferers are claiming unequalled relief from capsaicin.

Anecdotal evidence for the allergy fighting effectiveness of capsaicin is everywhere, and many doctors are reporting incredible results for their patients. As word of this success spreads, hot peppers are fast becoming recognized by the media as a true breakthrough in allergy relief. The new issue of “First For Women” magazine features an article about a woman who used cayenne pepper in tea to beat her chronic allergies, and Sinus Buster hot pepper nasal spray was even featured in the Wall Street Journal as a potential allergy cure.

A spokesperson for SiCap Industries, makers of Sinus Buster points out that this unusual hot pepper nasal spray has peaked the interest of physicians and researchers throughout the world. The company is presently beginning preliminary stages for their first allergy related clinical trials in partnership with researchers from a “well known” American medical university.

Although Sinus Buster is presently involved with two clinical trials in Europe, both of those concern general non-allergic sinus conditions and headaches. This "American" clinical trial will deal with allergic varieties of Rhinitis in one group and nasal polyps in another.

"We’re particularly excited about the allergic group, but we also have lots of anecdotal testimony from doctors and their patients concerning polyps. There’s no doubt capsaicin is a potential miracle drug when used properly. The real key for allergies is to use only the water soluble resins extracted directly from the plants. The amount of heat units is also a factor as are the differences in the capsicanoids and other compounds found in specific varieties of peppers. We spent years working out the right all around formula and our success rate against chronic allergies is quite incredible,” says Wayne Perry, founder of SiCap Industries.

Perry also points out that merely using cayenne powder in a tea, or even a few drops of pepper extract could help allergies, but they will never approach the effectiveness of pure hot pepper resins formulated with natural carriers and anti-oxidants as those in the Sinus Buster formula.

“The other important thing is you have to deliver the capsaicin through the nose to make it reach its’ full medicinal potential. A couple squirts of Buster three times a day will absolutely relieve most allergy symptoms, but you can also use it to combat and prevent allergy triggers altogether. That’s why it’s tough to do a good clinical trial using Sinus Buster because many sufferers have to take it as needed to reap the full benefits. The best clinical trial for us would also include a group of subjects who follow a daily dosage, but also use the spray as needed to combat their symptoms," Perry adds.

Either way it appears that hot peppers are becoming the doctor’s choice for allergy sufferers as more than 1,000 physicians now recommend Sinus Buster to their patients. Folk medicine has long advised eating hot peppers to help with chronic nasal congestion and many other conditions. Modern physicians know capsaicin relieves most chronic headaches, and Cardiologists regularly recommend a diet high in capsaicin to prevent the build up of dangerous blood clots that can lead to heart attack and stroke. Moreover, any idiot could tell you that eating hot peppers will clear your sinuses -- so just imagine what snorting them could do!

Just in time for allergy season, SiCap has launched a brand new retail box aimed at putting Sinus Buster hot pepper nasal spray on every cough and cold shelf in America. Sinus Buster is presently selling in more than 50 small retailers throughout the United States with additional outlets in Europe and Canada.

“Next month we’ll be in a bunch of stores throughout Canada thanks to a new distribution arrangement, and we’re about to premier in several large store chains here in the states. Of course you can always get Sinus Buster on our website. You can even buy it on Ebay from some of our retailers. The stuff is everywhere if you know where to look and it sells like crazy,” says Perry.

To find out more about Sinus Buster All Natural Hot Pepper nasal spray and allergies, visit (www.sinusbuster.com). Samples and information kits are available for qualified medical and media personnel upon request. Information about local Sinus Buster retailers is also available on the company’s website along with other relevant information.

Posted by Industrial-Manufacturing at 03:32 AM | Comments (0)

Research and Markets: Romania Medical Device Market Expected to Expand at a Rate of 6.4% Per Annum

Research and Markets (researchandmarkets.com/reports/c15344) has announced the addition of Romania Medical Device Market Outlook Report to their offering.

(PRWEB) April 11, 2022 -- Research and Markets (http://www.researchandmarkets.com/reports/c15344) has announced the addition of Romania Medical Device Market Outlook Report to their offering.


This report is ideal for executives wanting to understand the key drivers in medical markets worldwide. Each report provides a comprehensive analysis of the market and, importantly, provides 5-year forecasts by technology category, national data projections, outlook and key developments such as regulation, health facilities and government policy. Importantly, the market can be seen in its global context with international market comparisons.

Romania is located in south-eastern Europe, bordering Hungary, Ukraine, Moldova, Bulgaria and Serbia with one of the largest populations in this region. Improvements to the health system continue to be supported by World Bank-sponsored projects. The ‘Health Sector Reform Project APL II’ was approved in December 2004 and aims to improve maternity and newborn care, emergency medical care and rural primary healthcare.

In 2005, the Romanian market for medical equipment and supplies is estimated at US$240.9 million, or US$11 per capita. It is expected that the device market will continue to expand at a rate of 6.4% per annum. This will take the Romanian market to US$329 million in 2010. Around 92% of the medical device market is supplied by imports. The USA and Germany are the leading suppliers, accounting for over 60% of imports in 2002. The domestic production of medical devices contributes little towards the market size in Romania, and as a result, the value of exports is low.

Brief overview of contents of report:
1. Executive Summary
2. Medical Device Market
3 .Key National Data Projections
4. International Market Comparisons
5. Sources

For more information visit http://www.researchandmarkets.com/reports/c15344

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980

Posted by Industrial-Manufacturing at 03:31 AM | Comments (0)

Research and Markets: New Zealand Market for Medical Devices Estimated to Be US$237 million

Research and Markets (researchandmarkets.com/reports/c15418) has announced the addition of New Zealand Medical Devices Market Outlook - Market Intelligence Report to their offering.

(PRWEB) April 11, 2022 -- Research and Markets (http://www.researchandmarkets.com/reports/c15418) has announced the addition of New Zealand Medical Devices Market Outlook - Market Intelligence Report to their offering.

This report is ideal for executives wanting to understand the key drivers in medical markets worldwide. The report provides a comprehensive analysis of the market and, importantly, provides 5-year forecasts by technology category, national data projections, outlook and key developments such as regulation, health facilities and government policy. Importantly, the market can be seen in its global context with international market comparisons.

It is estimated the current size of the New Zealand market for medical equipment and supplies is US$237 million. This is equal to US$59 per capita, a similar level of spending to that found in Spain or the UAE, but around US$8 lower than in Australia. New Zealand is around the world’s 40th largest market, with an overall size similar to that in Romania or Hong Kong. New Zealand has very little domestic medical equipment manufacturing; what is produced tends to be exported. As a result, around 90% of the market is supplied by imports, primarily from the USA and Australia.

Contents of the report are as follows:
1. Executive Summary
2. Medical Device Market
3. Key National Data Projections
4. International Market Comparisons
5. Sources

For more information visit http://www.researchandmarkets.com/reports/c15418

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980

Posted by Industrial-Manufacturing at 03:30 AM | Comments (0)

e-MDs Announces Support for ASTM's Continuity of Care Record

There are two standards bodies today that are candidates for medical record interoperability, HL7/IHE and ASTM/CCR. While HL7/IHE is a mature and sophisticated standard, it is likely to be a more difficult and lengthy process for multiple vendors to conform to. ASTM's Continuity of Care Record (CCR) is better suited to the exchange of core patient health history. The standard is currently in the final ballot stage after years of work, and will have the potential to positively impact patient care almost immediately.

(PRWEB) April 11, 2022 -- e-MDs is announcing its public support for the Continuity of Care Record (CCR) as specified by the ASTM and major medical organizations, including the AAFP, AAP, and AMA. There are two standards bodies today that are the candidates for medical record interoperability. "We hope to 'break the tie'between HL7/IHE (Health level 7 and Integrating the Healthcare Enterprise) and ASTM/CCR by announcing our support of CCR" states Dr. David Winn, CEO of e-MDs. "We already have CCR in our system, and also have extensive HL7 functionality. They serve important and complimentary roles, but we believe CCR is better suited to the exchange of core patient health history. Importantly, the standard is currently in the final ballot stage after years of work based on the original, successful, Massachusetts referral form, and will therefore have the potential to positively impact patient care almost immediately." HL7/IHE is a mature and sophisticated standard, but likely to be a more difficult and lengthy process for multiple vendors to conform to, a requirement for the success of interoperability. e-MDs is a founding member of EHRVA (Electronic Health Records Vendors Association (www.himssehrva.org)) and a participant in CCHIT (Certification Commission for Healthcare Information Technology (www.cchit.org)), an organization entrusted with determining certification criteria for future EHRs. Dr. Winn believes e-MDs has the expertise to make this decision confidently, specifically noting "I personally attend the HL7 EHR technical committee meetings, am a member of CCHIT, and am intimately familiar with the HL7 RIM (reference information model) and messaging schema. The decision to adopt CCR was based purely on technical merits. We placed all politics aside. CCR is the logical foundation for future personal health records (PHRs) that patients will maintain themselves, and is something that is achievable in 2005."


ASTM International (www.astm.org) is a standards organization that has adopted the CCR as a future standard. EHRVA currently enlists 33 members representing 90-95% of all commercial EHRs. EHRVA is sponsored by HIMSS (Healthcare Information and Management Systems and Society (www.himss.org)), an organization that supports the use of information technology in healthcare.

About e-MDs
e-MDs is a leading developer of healthcare software solutions. Through e-MDs Solution Series they offer an integrated line of clinical, financial, and document management modules designed to automate medical practice processes and chart management. With their goal of improving patient care, decreasing physician errors, and increasing practice income, e-MDs has enjoyed one of the most rapid growths in the industry. Their sales growth is testament to a zealous focus on building the finest integrated EMR and practice management system, and offering it at a price any office can afford. For more information on e-MDs and CCR visit www.e-MDs.com.

Posted by Industrial-Manufacturing at 03:29 AM | Comments (0)

April 09, 2022

Raleigh Laser Hair Removal Safe, Effective, Comfortable Affordable Hair Removal

Raleigh Laser Hair Removal Safe, Effective, Comfortable Affordable Hair Removal

(PRWEB) April 9, 2022 -- Raleigh Laser Hair Removal expert and board certified plastic surgeon Dr. Michael Law Provides guidelines to consumers for choosing the appropriate Laser Hair Removal system and clinic.

Laser hair removal has come a long way since the first laser for hair removal received FDA clearance in the mid 1990’s. Older generation lasers were very slow, very painful and worked only on individuals with very dark hair and very light skin. Today, lasers can work on all skin colors. Laser Hair removal is now safer, faster, more comfortable and more affordable than ever before. When determining where to have laser hair removal performed, consider the following:

-Physician Supervision
Many laser hair removal centers today operate without a physician. It is important to be certain that a board certified physician owns and operates the facility and is available in case of a concern. To determine whether or not a physician is board certified, go to www.abms.org. Board certified plastic surgeons can be found at www.plasticsurgery.org

-Topical Numbing Preparations
These drugs are designed to help make laser treatments more comfortable but are totally unnecessary if using a laser with a DCD cooling system. If a patient uses a laser that requires topical numbing with a cream, he or she should be aware of all possible complications and contraindications in order to make an informed decision. In high concentrations, when used inappropriately, these drugs can be very dangerous.

-Cooling System
Each laser has a different way of cooling the skin. Some lasers use a topical cooling gel, others use a chilled tip. The most consistent, comfortable and safest way to cool the skin is with a Dynamic Cooling Device or DCD. Lasers that cool the skin using a DCD are very comfortable and there is no need for topical numbing preparations

-Spot Size
The spot size of a laser determines how much skin area can be covered per laser pulse. Lasers with larger spot sizes (18 mm) can cover more area much more quickly. For example, a laser hair removal treatment of the back or full legs could take as long as 2 hours with older lasers. Today, these areas can be completely treated in less than 20 minutes. The spot size not only determines the speed and comfort of the treatment, but the efficacy as well. The 18 mm spot size has been shown in studies to be more effective at removing hair than smaller spot sizes.

-Treatment Packages
Laser Hair Removal works on hair while it is in the growth phase only. At any given time, between 20% to 40% of the hair on any face or body area may be in a growth phase. Multiple treatments are required for complete clearance of the hair. However, each person may respond slightly differently. Laser hair removal centers should charge for just one treatment at a time. A reputable medical office or medical spa offering laser hair removal will offer individual treatments and not insist on payment of multiple treatments up front.

-Pricing
Because lasers for hair removal are much faster today than ever before, prices should be lower as well. An office offering laser hair removal can charge less for a laser hair removal treatment of the legs taking just 20 minutes vs. a 2 hour treatment with an older generation laser. Avoid centers offering “specials” on treatment packages, particularly if there is pressure to buy because a "special" is set to expire.

A complimentary consultation should be available for you to visit the facility, meet the laser technician and experience a spot test with the laser.

Staff members at a laser hair removal center should be able to answer questions not just about the laser they use, but about all lasers available for hair removal.

Blue Water Spa is a Plastic Surgery Medical Spa owned and operated by board-certified plastic surgeon Dr. Michael Law.

Dr. Law is the only solo practice plastic surgeon voted among the best in North Carolina 2003 and 2004. He has been featured in many national magazines and interviewed for news programs, but he has declined invitations to participate in plastic surgery reality television programs.

Kile Law, president of Blue Water Spa was recently appointed to the 2005 board of directors for the National Day Spa Association www.dayspaassocation.com. She is one of nine individuals nationwide chosen for this prestigious position. Kile is the winner of the 2004 ABBIE Award for best article in a professional skin care journal. Blue Water Spa has been featured in cover articles of many national magazines and spa publications such as the Medical Spa Report www.medicalspareport.com.

For more information, go to www.bluewaterspa.com or call (919)870-6066

Posted by Industrial-Manufacturing at 03:20 AM | Comments (0)

April 08, 2022

Officialrxdrugs.com is a One Stop, Low Cost, Online Pharmacy Super Mall, with Eight Virtual Stores Selling Prescription Drugs, Medications and Other Health Related Products

Officialrxdrugs.com is a virtual Super Mall with eight seperate stores to provide prescriptions, medications and other health related items at an affordable price. The Pharmacy Super Mall is a one time stop shop for all of their health needs.

(PRWEB) April 8, 2022 -- The Pharmacy Super Mall is a leader in providing health care products and medications at a substantial savings. The company believes that people should have access to affordable RX prescriptions and medications. Pharmacy Super Mall with its eight virtual stores, carries a complete line of the best brand named drugs, generic drugs and hundreds of vitamins and herbal supplements. The Pharmacy Super Mall at www.officialrxdrugs.com, carries an expanded line of pet medications and products such as hearing aids, eye glasses, and contact lens. An added bonus is Overseas RX Drugs, offers prescription drugs and other medications at rock bottom prices. Now, there is no need to contact Canada or Mexico for lower prices with this pharmacy online. Our website is not a regular pharmacy but a virtual, online Pharmacy Super Mall that offers choices and lower prices then your local pharmacy or drugstore.

Customers can talk comfortably online, by pushing a contact button on the website, with doctors and pharmacists by using their internet connection at home, their office or away on vacation. The prescriptions will be written and medications prescribed quickly, by saving time, not having to wait in a doctor’s office. Money is saved by purchasing lower priced prescriptions and no office fees are charged, not like a doctor’s office.

The Pharmacy Super Mall uses top physicians and trusted pharmacists, all located in the United States. All of our Doctor’s are fully licensed to practice in the United States and will do a simple medical history to rule out medications that may have an adverse affect on your health.

Our customers enjoy the procedure of purchasing their prescriptions and medications online from their own personal computer. Once the order is placed at www.officialrxdrugs.com, the customer will receive a receipt and the items ordered will be shipped to the customers door step. Purchasing prescriptions and medications online is a safe, private and easy way to seek treatment by using our expanded menu of products.

The website, www.officialrxdrugs.com, will be launched on April 8, 2005. All prospective customers are urged to contact the website and familiarize themselves with the discounts and savings on prescription drugs, medications and other health related items.

Posted by Industrial-Manufacturing at 05:55 AM | Comments (0)

April 07, 2022

Interactive Breathing Device Found Effective in Lowering High Systolic Blood Pressure

Frost & Sullivan Recognizes InterCure for Hypertension Treatment Technology Innovation

Montreal, Quebec (PRWEB) April 7, 2022 -- Frost & Sullivan has awarded its 2005 Hypertension Treatment Technology Innovation of the Year Award to InterCure, Inc. for its pioneering Interactive Respiratory-Pacing technology, and in particular for its device RESPeRATE To Lower Blood Pressure® - the only FDA-cleared non-drug medical device clinically proven to lower high blood pressure. The Award has been presented at the 2nd annual Excellence in Medical Devices Awards Banquet.

As over 60 million Americans suffer from hypertension and only approximately 30 percent of them successfully control their blood pressure, RESPeRATE® is expected to influence the treatment of hypertension extensively.

With multiple published clinical trials and thousands of advocates, both patients and physicians, RESPeRATE® is rapidly becoming a part of the standard of care for the treatment of hypertension. Besides being the only therapeutic self-care device treating a major cardiovascular condition, RESPeRATE® has become the first hypertension treatment available over-the-counter (OTC).

"This device uses a patented interactive respiratory-pacing technology to pace a patient's breathing from the normal rate of 14 to 19 breaths/minute, to the therapeutic zone of under 10 breaths/minute," explains Frost & Sullivan research analyst Miriam Nagel. "Within minutes, muscles surrounding the small blood vessels relax to allow the blood to flow more freely, reducing high blood pressure. When used 3 to 4 times a week for as little as 15 minutes at a time, RESPeRATE® was shown to reduce high blood pressure on a sustained basis by an average of 14/9 mmHg."

Nagel further explains that "This battery operated device, about the size of a paperback book, takes advantage of the body's natural tendency to follow external rhythms. The RESPeRATE® kit consists of a computerized control box, a respiration sensor, and headphones. By monitoring the patient's breathing rate and pattern, the device creates a personalized melody of two distinct tones - one tone for inhalation and one for exhalation," observes Nagel. "As patients listen to the melody and synchronize their breathing with these tones, the device gradually prolongs the exhalation tone, thereby pacing users to the slower therapeutic breathing zone."

In addition to RESPeRATE® To Lower Blood Pressure, InterCure has incorporated the technology platform in a second device, InTone™, a dyspnea-improving device for patients prone to mild-to-moderate heart failure. InTone™ has been tested successfully in Phase IIa clinical trials in which it has met or exceeded primary endpoints including significant improvements in QOL (quality of life), 6-minutes walk, ejection fraction, and pulmonary artery pressure. .

Frost & Sullivan presents its Technology Innovation of the Year Award to a company that has carried out new research that has resulted in innovations that have brought significant contributions to the industry in terms of adoption, change, and competitive posture. It recognizes the quality and depth of a company's research and development program, as well as the vision and risk-taking that enabled it to undertake such an endeavor in its industry.

Held in San Francisco, CA., Frost & Sullivan's 2005 Excellence in Medical Devices Awards Banquet honors world-class companies for outstanding performance and achievements in the medical devices industry.

About InterCure Inc.
InterCure (www.intercure.com) is a medical device company that creates and sells products that harness the therapeutic power of breathing for the treatment of hypertension, heart failure, respiratory diseases and other conditions. With 7 successful clinical trials, RESPeRATE® (www.resperate.ca), InterCure's first product, became the only non-drug medical device indicated by the FDA for the adjunctive treatment of hypertension. RESPeRATE® is cleared by Health Canada and is distributed in Canada by ManthaMed Inc.

Contact:
Tom Kirwan
201.720.7750 x 7136
e-mail protected from spam bots

About ManthaMed
ManthaMed is a Canadian distributor of accurate and reliable monitoring and diagnostic medical devices. Several of these leading edge medical devices are used in hospitals, physician offices and pharmacies for the diagnosis and monitoring of diseases such as diabetes, hypertension, cholesterol disorders, weight management, osteoporosis and asthma.

The company's mission is to improve patient access to early diagnosis and preventative care. More information is available at www.manthamed.com. RESPeRATE can be purchased online at www.resperate.ca.

Contact:
Peter Mantha
1-800-728-7327
e-mail protected from spam bots

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company founded in 1961, partners with clients to create value through innovative growth strategies. The foundation of this partnership approach is our Growth Partnership Services platform, whereby we provide industry research, marketing strategies, consulting and training to our clients to help grow their business. A key benefit that Frost & Sullivan brings to its clients is a global perspective on a broad range of industries, markets, technologies, econometrics, and demographics. With a client list that includes Global 1000 companies, emerging companies, as well as the investment community, Frost & Sullivan has evolved into one of the premier growth consulting companies in the world. For more information, visit www.frost.com.

Contact:
Stacie Jones
210.247.2450
e-mail protected from spam bots

Posted by Industrial-Manufacturing at 03:11 AM | Comments (0)

EM America Meets with Dr. Teruo Higa in Boston After Sponsoring Harvard Event on March 20

EM America met with Dr. Teruo Higa, discoverer of Effective Microorganisms (EM•1) and EM Technology, to discuss new sales and marketing objectives for the United States. EM Research Organization confirmed it wishes to see EM America expand its operations as the preferred provider of EM•1 products in the continental United States.

Boston, MA (PRWEB) April 7, 2022 -- Dr. Teruo Higa, developer of Effective Microorganisms (EM•1), met with the board of EM America to discuss future business ventures in the United States and abroad. Dr. Higa and EM Research Organization (EMRO) confirmed their wishes to see EM America expand its operations in the United States as their preferred provider of EM•1 products in the continental United States.

EM America’s Chief Medical Officer, Dr. Myron Murdock and Dr. Higa discussed upcoming clinical research with the dietary supplements EM-X and PRO EM•1. One such project is scheduled to begin in early May 2005. Dr. Murdock will document the results of his research later this year on his website, www.hisandherhealth.com and on EM America's website, www.emamerica.com.

Other technical applications for the EM•1 products were presented to the group. Tom Johnson, EM America's water specialist, discussed pending contracts and patents for wastewater and water treatments. Additionally, results from recent trials using EM•1 for odor control at poultry processing plants were presented.

The expanding use of EM•1 in golf courses across the United States was presented by Jeremy Murdock, EM America’s Vice President of Technical Applications. Several courses in the San Francisco Bay area and in Southern California have dramatically reduced their toxic chemical applications over the past three years by using EM•1 as part of their greens maintenance program.

Dwayne King, President of EM America, and Eric Lancaster, Executive Vice President of EM America presented the current status of sales and marketing to Dr. Higa, and other officials from EMRO, and EMRO USA. EM America’s first month of business grossed the highest sales to date since EMRO USA opened for business in November 2002.

Dr. Higa remarked, “I believe my dream for the spread of Effective Microorganisms in the United States will finally happen.”

EM America is based in Alto, Texas, with dedicated professionals covering a vast range of specialized applications including agriculture, human health, and the environment. EM America sells products manufactured and imported by EMRO USA Effective Microorganisms of Tucson, Arizona in the continental United States. Visit EM America online at www.emamerica.com.

EM Research Organization is based in Okinawa, Japan and is the owner of EM Technology and licenses the know-how in over 120 countries, partnering with for-profit and not-for-profit organizations.

For a list of offices around the world, please visit www.emtechnologynetwork.org.

Posted by Industrial-Manufacturing at 03:10 AM | Comments (0)

Amersin Subsidiary Receives 30 Million RMB Contract

Amersin Life Science Corporation announced today that its subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Company, has been awarded a 30 million RMB sales contract (approx. 3.6 million USD) to supply a range of homeostatic, antiviral and other pharmaceuticals in injectable form to Hubei Jiuzhoutong Pharmaceutical Ltd.

New York, NY (PRWEB via PR Web Direct) April 6, 2022 -- Amersin Life Science Corporation (OTCBB: AMLS) announced today that its subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Company, has been awarded a 30 million RMB sales contract (approx. 3.6 million USD) to supply a range of homeostatic, antiviral and other pharmaceuticals in injectable form to Hubei Jiuzhoutong Pharmaceutical Ltd..


Hubei Jiuzhoutong Pharmaceutical Ltd. is one of the largest, and the fastest growing privately owned, pharmaceutical distribution companies in China. It has established sales and distribution networks throughout China.

"We are pleased to enter into Hubei Jiuzhoutong Pharmaceuticals’ large distribution network,” said Mr. Reid Li, President of Amersin Life Sciences Corporation. "This is the first time our subsidiary has received a single contract of this size from such a well established distributor. Our products will be sold into new markets through their sales network creating additional demand in the future. It is the beginning of a strategic relationship we believe will lead to many other opportunities as we continue to restructure our products lines to increase capacity and introduce additional products that fit within Hubei Jiuzhoutongs’ established channels."

About Amersin Life Science Corporation
Amersin is engaged in the acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to include all facets of pharmaceutical life sciences from raw materials through dosage form production and distribution. Its' recent acquisition of a controlling interest in the profitable Hubei Tongji Benda Ebei Pharmaceutical Co. subsidiary is a cornerstone in its plan to expand through strategic acquisition and vertical integration to become one of the leading American corporations to profit from the burgeoning life sciences sector in China. The Hubei Tongji subsidiary is one of the largest capacity producers of small form injectable pharmaceuticals in central China. Shareholders may access additional information via the Company's website at www.amersin.com.

"Safe Harbor" Statement: This news release contains certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the forward-looking statements contained herein. Detailed information about many risk factors are set forth in Amersin’s periodic filings with the Securities and Exchange Commission including, but not limited to, those risks and uncertainties listed in the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Management’s Discussion and Analysis" in Amersin’s most recent Quarterly Report on Form 10-QSB. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov or the Amersin web site at http://www.amersin.com. Amersin is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, contact:
Corporate Communications:
Amersin Life Sciences Corporation
Howard Milne, 604-881-2899 ext 220
Fax: 604-881-2892

Posted by Industrial-Manufacturing at 02:58 AM | Comments (0)

April 06, 2022

A Timely (SMS) Message For The Patient

Government health departments are still waiting for a return on large investments in IT infrastructure. However, according to a report to be published later this week by Cambridge based analysts Wireless Healthcare, a simple mobile phone based service is already having an impact on hospital performance data. - Report finds that SMS text messaging is having an impact on hospital performance data.

Cambridge, UK (PRWEB) April 6, 2022 -- Government health departments are still waiting for a return on large investments in IT infrastructure. However, according to a report to be published later this week by Cambridge based analysts Wireless Healthcare, a simple mobile phone based service is already having an impact on hospital performance data. The report, ”Mobile and Wireless Services For Outpatients”, draws attention to reduced ‘Did Not Attend’ (DNA) rates (missed appointments) in outpatient clinics that use SMS based appointment reminder systems.


The report notes that revenues from SMS patient reminder services will grow relatively slowly over the next five years from a low base and are unlikely to exceed £1 million per annum by 2010. Theoretically, if every patient in the UK were sent a text message reminding them of their appointment, mobile communications providers would receive revenues in excess of £20 million per annum. However, Wireless Healthcare feel it is unlikely that health providers will migrate more than a small proportion of patients from paper based systems to the current generation of mobile services.

The report reveals that SMS patient reminder systems have reduced some outpatient clinics’ DNA rates by up to 30% in spite of the fact that less than 20% of patients choose to use the service. “The patients most likely to forget, or not bother, to turn up for appointments fall within the 16 to 35 age group,” notes Peter Kruger, Senior Analyst with Wireless Healthcare, who goes on to point out, “by a lucky coincidence people in this age group are heavy users of mobile phones and text messaging. This is one reason why text message based reminder systems have been successful from day one.” However, Wireless Healthcare warns that this early success could result in diminishing returns as reminder services are expanded.

In the report Wireless Healthcare points out that SMS patient reminder services provide mobile communications vendors with an ideal entry point into the healthcare IT market. Wireless Healthcare sees vendors who become established in the market leveraging their position by adding services, such as patient support and medication reminder and compliance monitoring, to their existing messaging platform. The report sees evidence that this is already happening in the field of mental healthcare where outpatient clinics and social services are under political pressure to ensure that patients keep appointments and comply with medication regimes. The report also sees a number of established IT vendors adding patient reminders to the list of outsourced services they offer hospitals.

Another wireless technology that is being used by outpatient clinics is patient paging. Wireless Healthcare’s report concludes that sales of these systems, which currently use proprietary networking technology, could come under pressure as restrictions on the use of mobile phones in hospitals are lifted. Then text-messaging vendors will start providing systems that alert patients who are waiting within the outpatient clinic itself. Wireless Healthcare notes that the ease with which patient paging can be deployed, and its relatively low cost, have been instrumental in the rapid growth in sales of systems to outpatient clinics. While patient paging is currently marketed as a technology that improves the patient’s experience of the outpatient care process, it could, according to the report, when integrated with Patient Administration Systems (PAS), also be used to increase a hospital’s workflow efficiency.

The report “Mobile and Wireless Services For Outpatients” is available from www.wirelesshealthcare.co.uk

About Wireless Healthcare.
Wireless Healthcare are UK based analysts and consultants specializing in the application of mobile and wireless technology in the healthcare sector.

Additional Information For Editors.
Sample graphs from this report are available:-
www.wirelesshealthcare.co.uk/wh/smsprdata.doc

For further details contact:
Toby Jackson
Wireless Healthcare
e-mail protected from spam bots

Posted by Industrial-Manufacturing at 04:24 AM | Comments (0)

April 05, 2022

Networks Plus Partners with Leading HIPAA Compliance Software Manufacturer

Network security expert, NPTG, provides end-to-end solution.

San Diego, CA (PRWEB via PR Web Direct) April 5, 2022 -- Networks Plus Technology Group, a leading national provider of technology solutions, and HipaaManager, Inc., a well recognized and heavily endorsed leader in HIPAA Compliance, today announced a strategic distribution agreement. As part of the agreement, Network Plus will distribute HipaaManager’s two software product lines known as HCAT™ (HIPAA Compliance Assessment Tool) and RCAT™ (Risk Control Analysis Tool).


HCAT™ is co-authored by PrivaPlan Associates, Inc. an organization endorsed by the California Medical Association, the Connecticut State Medical Society, and the Louisiana State Medical Society. Several state medical associations, trade groups and professional associations including the Medical Society of the State of New York and Vermont Medical Society also endorse HCAT™. HCAT™ is a web-based application tool that assesses a current medical environment and corresponding HIPAA security compliance level. The user-friendly software provides a clear, concise, easy to understand roadmap towards reasonable and appropriate HIPAA compliance specific to the office in need.

The strategic distribution agreement allows Networks Plus to bundle and distribute the HipaaManager products with their IT solution sets. This total solution approach enables a more complete and cost-effective HIPAA Security solution to all organizations affected by the upcoming April HIPAA Security deadline.

This is an incredible opportunity for Networks Plus to partner with a company that has received this level of endorsement from multiple state medical associations. HipaaManager’s software platforms, HCAT™ and RCAT™, have the capability of taking a very complex dilemma for medical institutions (HIPAA compliance) and simplifying it for them, taking some of the pain and confusion away associated with HIPAA Security compliance issues. This simple software tool processes and documents ePHI specifications, revolutionizing the approach to becoming HIPAA compliant. "The software is the TurboTax™ for HIPAA, and makes compliance a cinch," stated James Kernan, President of Networks Plus.

HipaaManager will leverage Networks Plus’ national distribution capabilities as an established provider in hardware and software procurement. Remediation and professional services are also core competencies for Networks Plus, and will allow for turnkey solutions for the medical industry.

"We are extremely pleased to work with a well-respected technology leader like Networks Plus," said Mike Sawyer of HipaaManager, Inc.

Adds Chris Piecukonis, Vice President of Professional Services for Networks Plus, "The company has a strategy of working in partnership with key manufacturers to deliver value-added technology solutions. We are delighted to reach an agreement with HipaaManager, a company with products that are highly regarded for quality, performance and competitive pricing. We will work closely with our new, esteemed partner to provide our customers with the ideal blend of powerful yet economical IT security solutions that solve their business problems while ensuring compliance with mounting legislative and business continuity requirements."

About Networks Plus Technology Group (NPTG)
Networks Plus Technology Group, Inc. (NPTG) is headquartered in San Diego, California. Formed in April of 1994, the company has become one of the most complete technology service providers in the country, with core competencies including product acquisition, network security, network storage, network management, CRM, and technical staffing. As a premier provider of total information technology solutions, NPTG has been ranked as one of the fastest growing companies in the country.

About HipaaManager, Inc.
HipaaManager, Inc., a leading source of HIPAA Privacy and Security solutions, and creator of HCAT™ and RCAT™, offers cost-effective HIPAA solutions that are appropriate for healthcare providers. HipaaManager customers range from small to large practices, hospitals, and health plans. Endorsed by various state and local healthcare organizations, HCAT(TM) is a scalable, cost-effective, and web-based solution that helps users find a clear, concise, and easy to understand roadmap towards reasonable compliance measures.

Media Contact:
Mimi Smith
Marketing
(858) 386-5100 x225
e-mail protected from spam bots

Posted by Industrial-Manufacturing at 02:53 AM | Comments (0)

April 04, 2022

A Default Judgment Has Been Entered Against Pharmaceutical Company, Kinetana (Group), in Suit Citing Corrupt Organization, Civil Racketeering, Intentional Misrepresentation & Breach of Contract.

A default judgment was entered against Kinetana International Biotech Pharma Limited, a publicly trade company on the stock exchange of Hong Kong, in a suit filed late last year by Morena Vista Trading LLC seeking damages of $6 million for intentional misrepresentation, breach of contract, civil racketeering and corrupt organization practices. Other parties named in the suit were Dr. Yun Kau Tam (also President of Novokin BioTech Inc.), Dr. Nuzhat Tam-Zaman, Mr. Sui Leung Yeung, Kinetana Group Inc., Kinetana U.S.A., Kinetana Holdings(BVI)and Kinetana Holdings (Barbados).

(PRWEB) April 4, 2022 -- A default judgment was entered against Kinetana (Group) on March 8, 2022 in the United States District Court, Central District of California (Case No. SACV-05-134 CJC) when the company did not respond to the suit filed late last year by Morena Vista Trading LLC on December 30, 2004.

Morena Vista Trading filed its case No. 04CC12637 in the California State Superior Court seeking damages and relief of $6 million, citing instances of intentional misrepresentation, breach of contract, civil racketeering and corrupt organization practices by the companies and their directors Dr. Yun K. Tam,president of Novokin Biotech Inc, Dr. Nuzhat Tam-Zaman and Mr. Sui Leung Yeung.

Kinetana is a pharmaceutical company publicly traded on the Growth Enterprise Exchange of the Hong Kong Stock Exchange with principal places of business in Edmonton, AB Canada and Hong Kong.

Morena Vista Trading, a California based strategic business development & marketing company, formed a joint venture with Kinetana in April of 2004 to establish sales of Kinetana products in the U.S. and Canada.

The default judgment was entered after Kinetana failed to respond to the charges made by Morena Vista Trading LLC who is seeking damages and relief from the companies and its directors Dr. Yun K. Tam, Dr. Nuzhat Tam-Zaman and Mr. Sui Leung Yeung for intentional misrepresentation and breach of oral and written contracts resulting in loss of invested monies, business opportunities and unjust hardship due to willful misrepresentation.

Posted by Industrial-Manufacturing at 03:41 AM | Comments (0)

New Sales Strategies for UK Companies Entering US Market

“How to Quickly and Cost-effectively Enter the U.S. Market” – Georgia, USA alliance to conduct U.K. Workshops on Selling in the United States in April.

Savannah, GA (PRWEB) April 4, 2022 -- The APH Group, Team Logistics and The Swainsboro/Emanuel County, Georgia Joint Development Authorities are pleased to present a Workshop for U.K. businesses that would like to sell their products in the United States.

Many United Kingdom companies ignore U.S. trade because of the perceived high costs involved and the difficulty of doing business in such a large, diverse market. By doing nothing, they are missing out on significant opportunities to export their products to the third largest world market with the highest discretionary income in the world.

These workshops will explore U.S. market entry utilizing a Partner Team Approach - a one-stop source incorporating sales, marketing, logistics and economic development programs customized to facilitate your company's U.S. market entry.

Workshops will be held in Birmingham on April 19, 2022 and in Manchester on April 20, 2005.

Workshop topics will include:
- Discussion about the cost of U.S. Sales Channels and how to shorten the supply chain to achieve greater profits
- Sales Outsourcing as an Entry Strategy – a cost-effective way to have an immediate sales presence in the U.S.
- A One-Stop Approach to the Logistics of Doing Business in North America – Customs, logistics and warehousing through one company – getting your products from your dock to the end user.
- U.S, State & Local Tax & Economic Development Incentive Programs Available to UK Companies along with advantages of locating a value-added, distribution or manufacturing facility in the U.S.
- Sales Incubators for Start-Ups and Small Businesses and Industry Groups

Participation is recommended for Managing Directors, Division Managers, Sales and Export Managers.

Workshop fee is £ 50.00.

"Hit the Ground Running" -- Learn how to quickly and cost-effectively begin or increase your U.S. sales efforts.

Register at www.aphgroup.us or call 912 352-1805.

About The APH Group
The APH Group was founded in 1996 and initiated its Sales Outsourcing Services in 2003 to overseas companies wishing to enter the United States market. They provide the Missing Link to trade in North America with their extensive experience and knowledge in developing entry strategies, hiring and managing U.S. salesforces. They provide a complete turn-key sales operation that handles sales, marketing, administration, shipping, export logistics and warehousing.

The APH Group is the exclusive site consultant of the Swainsboro/Emanuel Department of Economic Development which assists overseas companies locate U.S. facilities in Swainsboro, Georgia.

The APH Group is headquartered in Savannah, Georgia with an office in London, England and Business Developers in the United Kingdom, Germany, Turkey, Israel, South Africa and Brazil.

For additional information, please see http://www.aphgroup.us

Contact Information:
Susan Brod, CEO
The APH Group
Phone
912 352-1805 Savannah, GA
020 7016 2673 London, UK
E-mail: e-mail protected from spam bots
URL: http://www.aphgroup.us/

Posted by Industrial-Manufacturing at 03:39 AM | Comments (0)

New Book Suggests Surgery For Prostate Cancer No Longer Necessary in Most Cases: More Men Now Choose High Tech Radiation Therapies

A new book, Surviving Prostate Cancer Without Surgery, is the first to report that the majority of prostate cancer patients are now forgoing surgery in favor of state-of-the-art radiation therapies. The authors are members of one of the country's premier cancer care teams, the Dattoli Cancer Center & Brachytherapy Institute located in Sarasota, Florida. The most up-to-date and comprehensive guide for patients and their families explains how radioactive "seeds" and "smart beams" have made the scalpel obsolete.

Sarasota, FL (PRWEB) April 4, 2022 -- During the 1990's most prostate cancer patients had their prostates removed by the surgical procedure known as radical prostatectomy. But in more recent years, radical surgery has fallen increasingly out of favor. The majority of prostate cancer patients now avoid the knife by opting for more effective, state-of-the-art radiation therapies.


That trend is reported in a new patient guidebook, Surviving Prostate Cancer Without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle, coauthored by members of a leading radiation oncology team under the direction Dr. Michael J. Dattoli of Sarasota’s Dattoli Cancer Center. Citing the most recent medical studies and Medicare statistics, this is the first book to report that advanced radiation therapy has now replaced radical prostatectomy as the mainstream treatment of choice for most early stage prostate cancer patients. The issues involved are similar to those raised by radical mastectomies for the treatment of breast cancer, which can also be treated by less invasive methods.

According to Dr. Dattoli, one of the pioneers of high tech radiation research in this country, the new ‘Gold Standard’ treatment for prostate cancer is a cutting edge protocol that combines radioactive seed implants (brachytherapy) with advanced external radiation therapy, known as Intensity Modulated Radiation Therapy (IMRT).

With one of the highest cure rates in the country and numerous peer-reviewed studies to his credit, Dr. Dattoli explains, “The greater than 10-year disease-free survival rate for patients who have completed our brachytherapy protocol is superior to surgical removal of the prostate, with far less risk of complications such as erectile dysfunction and incontinence. Recent advances in the delivery of high energy photons, ultrasound imaging, and computerized treatment planning have essentially turned the tide against what was previously thought to be a disease most effectively treated by means of radical surgery. In just the past few years, we have seen a revolution in the field.”

The director of the Dattoli Cancer Center & Brachytherapy Institute, Don Kaltenbach, himself a 14-year prostate cancer survivor, suggests, “With increased awareness, more men are choosing not to go under the knife because they want to avoid the high risk of complications. We now have sophisticated, non-invasive treatments like seed implants and IMRT that have proven more effective in curing the disease, while preserving quality of life for most patients. In recent years some high-profile prostate cancer patients such as Colin Powell and Robert Deniro have had prostatectomies, but more men are now following the example of former New York City mayor Rudolph Giuliani, whose prostate cancer was successfully treated with seed implants.”

In Surviving Prostate Cancer Without Surgery, Dr. Dattoli discusses all the pros and cons of the currently available treatments. He points out, “Many surgeons don’t inform their patients that even in the best surgical hands there is a great likelihood that a man will be wearing diapers the rest of his life, and he is also very likely to suffer from erectile dysfunction, even with Viagra and similar remedies. We now know that in addition to those unwanted side effects, surgical removal of the prostate leaves behind cancer in as many as half of those patients who are characterized as intermediate or high risk. To a large extent, the increasing popularity of brachytherapy and IMRT has been patient-driven, with men doing their homework, joining support groups and searching the Internet. At this time, an overview of prostate cancer care and treatment from a non-surgical perspective is crucial for every patient wishing to receive the highest standard of care.”

IMRT is the most advanced form of external radiation therapy, often referred to as ‘Smart Beam’ technology because of its extraordinary ability to direct thousands of precisely targeted radiation ‘beamlets’ into the tumor itself while avoiding healthy surrounding tissue. Dr. Dattoli explains, “Our protocol typically combines IMRT with brachytherapy in order to increase the dose and more effectively eradicate the cancer. Even higher risk patients (those with high PSA values and high Gleason scores) have enjoyed a greater than 80% survival rate in our program, while low risk patients have a success rate of more than 90%. As we discuss in our book, we now have every reason to believe that the vast majority of early state prostate cancer patients can be cured without surgery.”

Unlike other books on the subject, Surviving Prostate Cancer Without Surgery provides patients with advice from three essential points of view: physician, nurse, and patient-survivor. Drawing on their shared experience, the book is intended to guide patients step-by-step through diagnosis, treatment and recovery. “Knowing what to expect is one of the keys to beating this disease,” says Kaltenbach. “We want to prepare patients for the journey ahead, regardless of which particular treatment they may choose for themselves. We want them to be fully informed.”

Published by Seneca House Press and the Dattoli Cancer Foundation, Surviving Prostate Cancer Without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle is available from bookstores and Amazon.com, or by calling the trade distributor, Pathway Book Service at (800) 345-6665.

Paperback. 284 pages. 22 color photographs, index, glossary, resource directory. ISBN: 0-9640088-8-2. Pub date: March 28, 2005.

Additional information can be obtained from the Dattoli Cancer Foundation by calling (800) 915-1001, or by visiting the Web site: http://www.pca-survivingwithoutsurgery.com

Posted by Industrial-Manufacturing at 03:38 AM | Comments (0)

Mediabids, the Only Online Print Ad Space Marketplace, Saves Client, The Vacation Consultant 74 Percent On Magazine Advertising Costs

Print media broker saves client 74 percent on magazine advertising costs

Winsted, CT (PRWEB) April 4, 2022 -– Certified Aruba expert and travel specialist, The Vacation Consultant , thevacationconsultant.com, came to Mediabids.com for help reaching a diverse group of like-minded travelers who needed the guidance of their expertise for such locations as the Bahamas, Carribean & South Pacific.


Mediabids.com’s media planner Kris Cianciolo was able to deliver magazine advertising space at a savings of over 74 percent in three national consumer magazines. Through Mediabids, The Vacation Consultant paid $930 for over $3,550 of advertising space; three full-color insertions and one b/w insertion.

"As a small business owner I'm new to advertising and all the avenues one can pursue. When I first spoke with Kris Cianciolo, I didn't think I had enough money or "know how" to get anything significant. I couldn't have been more wrong. I felt like Kris was just as invested in my business as I am and looked forward to our morning calls. With her help I was able to get four ads (two full-page, full-color) in three national magazines for less than $1000! I am still astounded and will no longer waste time or money going to outlets direct. Mediabids is my company's new advertising department!"- Elena Mathis, President, The Vacation Consultant, thevacationconsultant.com.

Register your business or find more information on this easy way to purchase newspaper advertising and magazine advertising on www.MediaBids.com or call direct at 866-236-2259. Registration is free, simple, and confidential.

The average savings offered to businesses needing to purchase newspaper advertising and magazine advertising is 61% on advertising rates. Advertisers are never obligated to make a purchase if they are not satisfied with the offers received from publications. There is no fee to use Mediabids services, advertisers pay only for the price of the newspaper advertising and magazine advertising space they purchase.

About MediaBids.com
Mediabids has developed a better way for advertisers and publications to buy and sell newspaper advertising and magazine advertising. Mediabids, the newspaper and magazine advertising auctioneer, offers a unique opportunity for advertisers and publications to tap into new markets, increase revenues and save on costs traditionally associated with print advertising. A Connecticut-based newspaper company founded Mediabids in 1999 as a tool to streamline and enhance the relationship between advertisers and print media outlets.

Posted by Industrial-Manufacturing at 03:37 AM | Comments (0)

The Link Between Diabetes And Dry Eye

If you have diabetes there is about a 50-50 chance that you have dry eye. Dry eye is characterized by dryness, burning or sandy-gritty irritation in the eyes that gets worse as the day goes on. Dry eye in diabetes is a result of decreased corneal sensation or relative numbness of the surface of the eye. This relative numbness of the surface of the eye has also been associated with diabetic retinopathy. What is dry eye, what causes it and what can be done about it?

(PRWEB) April 4, 2022 -- If you have diabetes there is about a 50-50 chance that you have dry eye. Dry eye is characterized by dryness, burning or sandy-gritty irritation in the eyes that gets worse as the day goes on. Dry eye in diabetes is a result of decreased corneal sensation or relative numbness of the surface of the eye. This relative numbness of the surface of the eye has also been associated with diabetic retinopathy. What is dry eye, what causes it and what can be done about it?

The tears on the surface of the eye are a salt solution. The surface of the eye needs these tears because the delicate living cells on the surface of the eye have no blood supply—it has a tear supply instead. So rather than getting important things like oxygen and electrolytes from the blood, it gets them from the watery layer of the tears. This watery layer is so important that it is covered by a layer of oil produced by the oil glands in the eyelid that protects it from evaporation.

The first thing that happens when an eye becomes dry is that the tears lose water and become too salty. Just like when you throw salt on a wound it causes stinging and burning, when your tears become too salty they cause stinging and burning of the eye surface. As the eyes become drier this becomes a sandy-gritty irritation of the eyes.

Dry eye is one of the most common conditions affecting the eyes. It affects approximately 14% of people over the age of forty, and the prevalence increases with age. This is because there are so many ways to get dry eye. Anything that decreases tear production or increases tear evaporation may cause dry eye.

Long-term hard contact lens wear, LASIK eye surgery, certain viral infections of the cornea, and diabetes all may cause decreased corneal sensation and, with it, the decrease in tear production that results in dry-eye irritation.

Many people choose to treat dry eyes with eye drops. It used to be that all artificial tears were pretty much the same. They were designed to cover up the dry spots that appear on the eye in advanced cases of dry eye. These drops were developed before it was realized that dry spots don’t cause dry eye but are a result of the tears becoming too salty. These drops would provide temporary relief of dry eye but the dry eye would never get better.

Recently it was discovered that just as the electrolytes in the blood are biologically active, the electrolytes in the tear film are biologically active as well. It turns out that if the content of an artificial tear does not precisely match this electrolyte balance, the drop can “starve” the surface of the electrolytes it needs and decrease the quantity of lubrication. So in effect, with these drops, patients take one step forward, but also one step back.

There is another way to accelerate dry eye relief, and possibly even obtain complete dry eye relief. In a study of nearly 33,000 female health professionals it was found that the more omega-3s they ate, the lower their risk for dry eye. This is actually the third study that has linked dry eye to a dietary deficiency of omega-3s. Omega-3s are “essential fatty acids” that are scarce in the American diet. They can be obtained from salmon, sardines, herring, and tuna.

Tuna is the number one source of omega-3s in the American diet, but now the FDA warns Americans not to eat it more than twice a week because of problems with high mercury content. To provide a healthy source of omega-3s for relief of dry eye irritation for those who won’t, don’t or can’t eat sardines every day, TheraTears Nutrition for Dry Eyes (omega-3 supplement with flaxseed oil, fish oil and vitamin E) is a great way to get the omega-3s that you need.

The omega-3s in TheraTears Nutrition seems to help provide dry eye relief in three ways. First, omega-3s improve eye comfort by suppressing inflammation. Second, the oil glands in the eyelid use essential fatty acids to manufacture the oil layer of the tear film. TheraTears Nutrition provides the omega-3s your oil glands need to make a healthy protective layer of oil that coats the tear film and makes dry eyes feel better. Finally, the omega-3s work together to protect the tear gland and help it make more tear fluid.

In addition to soothing the symptoms of dry eye, omega-3s carry other benefits for diabetics. High dietary intake of omega-3s correlates with a lower incidence of type 2 diabetes, omega-3 have been shown to reduce elevated triglycerides in non-insulin dependent diabetics, and even more importantly, omega-3s reduce the risk of death from coronary heart disease and total mortality in diabetic women.

If you have dry eye and diabetes, you are not alone. There are excellent treatments available that can greatly add to your health and comfort.

Article Written By Jeffrey P. Gilbard, MD
Clinical Assistant Professor, Harvard Medical School
Founder, CEO & Chief Scientific Officer, Advanced Vision Research

Posted by Industrial-Manufacturing at 03:36 AM | Comments (0)

Are You Prepared For The Next Pandemic? Innovative Health Advances May Save You From the Bird Flu and SARS

The warnings for this flu season are ominous. Although it has been mild so far, we are being told to prepare, for the worst is yet to come. The World Health Organization (WHO) warns us the planet is overdue for a killer flu outbreak, or “pandemic.” The last serious pandemic was in 1918 when an estimated 40 million people died.

(PRWEB) April 4, 2022 -- The warnings for this flu season are ominous. Although it has been mild so far, we are being told to prepare, for the worst is yet to come. The World Health Organization (WHO) warns us the planet is overdue for a killer flu outbreak, or “pandemic.” The last serious pandemic was in 1918 when an estimated 40 million people died.

Already decimating poultry populations in East and Southeast Asia, the lethal “Bird Flu” is poised to become the most devastating pandemic in human history. A serious strain of this killer flu could travel around the globe in a matter of days. The world is unprepared for such an event.

Vaccination, our primary defense against influenza, helps protect us against the next flu season but will not protect against up and coming strains. In fact, manufacturers have been wrong about the “up and coming” strains for the past three years. If we cannot depend of a flu shot, what can we do to protect ourselves against such an enormous threat?

“We can’t just hope that we don’t get sick,” says Marc Rose, M.D. “Strengthening the immune system is absolutely imperative.” With prescription medicines designed to treat existing conditions, the medicinal property of natural supplements may be the answer we are looking for.

“The problem with supplements is that many of the beneficial nutrients are either destroyed by the acids in the stomach or the indigestible capsule containing the nutrients passes through the body intact,” says Dr. Rose. “Fortunately, a revolutionary new advancement is helping to alleviate this problem.”

This innovation has had far-reaching implications and has led to the development of a product which utilizes this innovative technology to successfully deliver a combination of all-natural, selected anti-oxidants which greatly boost the immune systems.

“Because it has proven to be so effective in fighting off influenza and other ilnesses, I recommend Anti-Max for all of my patients,” says Dr. Rose. Anti-Max combines an elderberry fruit compound, a ginger oil compound, a green tea extract, and Nigella sativa oil. These natural ingredients contain anti-viral, anti-inflammatory, anti-emetic, anti-carcinogenic, and anti-microbial properties. These natural herbs, oils and fruit strengthen the immune system which greatly enhances your body’s ability to fight off infection and illness including influenza, SARS, and other illnesses.

Selected SARS patients in the Toronto, Canada outbreak, voluntarily took Anti-Max and recovered significantly faster than those using traditional medicines alone. This is a very exciting development in disease prevention, and formal clinical trials are pending. With influenza, SARS, and a possible “Bird Flu” outbreak, people need all the weapons they can get to fight off these sicknesses.

Posted by Industrial-Manufacturing at 03:34 AM | Comments (0)

April 02, 2022

Baxa CEO Greg Baldwin Is Now Profiled at the Expert Information for Journalists Website and Available to Address Selected Business Topics

Greg Baldwin, Chairman and CEO of Baxa Corporation of Englewood, Colorado, is now profiled on the Expert Information For Journalists website – Expert411.com. Baxa Corp., a privately held company is a leader in serving hospital pharmacy systems for handling, packaging and administering liquid medications from oral to multi-ingredient IV. Baxa is a registered medical device manufacturer with the FDA and has sales in over 35 countries.

Englewood, CO (PRWEB) April 2, 2022 –- Greg Baldwin, Chairman and CEO of Baxa Corporation is now profiled on the Expert Information For Journalists website at http://expert411.com/_wsn/page7.html. Topics he is prepared to address for media interviews include the following:

* Business Strategy
* Organic Growth Versus Venture Capital
* Lean Manufacturing Process
* Building a Strong Management Team
* Six Sigma Implementation

Baldwin is a standard-bearer for organic growth strategies in business and often speaks to organizations addressing the topic of "business growth without venture capital." He is a proponent of simplified strategic planning and has been a strong advocate for lean manufacturing practice, Six Sigma and investment in research, development and product planning activities. Baldwin is responsible for leading the Baxa Corporation's sales growth from $26.5 million in 1997 to more than $65 million in 2004. Through his leadership, Baxa met the regulatory challenges of ISO 13485 and EN46001 (CE), while achieving operational excellence through the adoption of lean manufacturing processes and Six Sigma. Baldwin is responsible for developing a strong management team for the company as well as implementing its successful strategic planning process.

Recently named to the Healthprolink (Bellevue, WA) Board of Directors, Baldwin formerly served as President of and CEO of Baxa Corporation from November, 1997 to April, 2003. He had been Senior Vice President for Worldwide Sales and Marketing at Baxa since joining the company in 1993.

Prior to joining Baxa, he worked for ten years in sales and marketing management for the telecommunications industry. A graduate of Bowdoin College (Brunswick, ME), Baldwin holds an MBA from Boston University, serves on the Board of the Colorado BioScience Association and is a Trustee of Denver Academy, a grades 3-12 school for children with learning differences.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.

Contacts:
Marian Robinson, Vice President, Marketing, Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots
http://www.baxa.com

Maggie Chamberlin Holben, APR, Absolutely Public Relations: 303.984.9801 or 303-669-3558,
Email: e-mail protected from spam bots
http://www.absolutelypr.com

Posted by Industrial-Manufacturing at 04:32 AM | Comments (0)

April 01, 2022

By Offering an Anodyne (Pain Alleviating) Infrared Therapy Product called RevitaMed, LymphaCare Corp. Meets Sales Goals for 1st Quarter of 2005.

Anodyne is a word defined in the dictionary as "to alleviate pain". RevitaMed's Infrared Therapy System has been doing just that for hundreds of neuropathy and chronic pain patients, while helping the LymphaCare staff meet its goals.

(PRWEB) March 31, 2022 -- LymphaCare's Revitamed division has seen a steady increase in sales of both patient and clinical models of the RevitaMed Infrared Therapy System.


Patients and therapists that have seen or evaluated the RevitaMed System for treating chronic pain and circulation problems tend to be surprised and impressed. Most have been unaware that there was any competition or alternative to the more well known brand name of Anodyne® Therapy.

Recently a physical therapy clinic in Oregon that was evaluating an Anodyne® Therapy system in their facility, decided to purchase the RevitaMed Therapeutic System based on the information provided by LymphaCare and their knowledgeable consultants without even an evaluation. That clinic has since purchased a second RevitaMed Professional System. http://www.revita-med.com

RevitaMed’s Professional system tends to cost about 20%-30% less than the Anodyne® Therapy Pro unit. Physicians, Chiropractors, Physical & Occupational Therapists, and other professional users love the size of the pads, especially the unique boot pads, which cover the entire foot & ankle. One Oregon clinic is seeing excellent outcomes for their neuropathy patients. They are also utilizing the "boot" pads to treat large surface areas of the back and leg. They have also seen good results treating the painful medical condition of shingles.

Patients have also been discovering why RevitaMed works so well. The Anodyne® Therapy system is priced at $2995.00 for a new home system. RevitaMed is well over 50% less depending on the pad combination. Many patients that don’t qualify under their insurance, nor have the time to go to physical therapy are thrilled to buy a RevitaMed at a more reasonable price with much larger more powerful infrared pads.

Customers have pointed out that the equine or Equilight (http://www.equilight.com/Products.htm) horse product affiliate of Anodyne ® Therapy, sells the same $29950.00 patient home unit for just $2395.00 on the Equilight.com website That’s a $600.00 difference for what is essentially the same product! This has been raising some serious questions.

The RevitaMed Infrared Therapy consultants at LymphaCare have comforted customers by addressing the questions and concerns for those evaluating Infrared treatment systems. RevitaMed plans on being around for many years. They are in the process of publishing several clinical studies, and enhancing their current product line to address customer needs and requests.

LymphaCare has been able to meet their sales targets, by educating customers on infrared therapy product differences, reimbursement issues, RevitaMed's excellent pricing, and 30 day money back guarantees for neuropathy patients.

Diabetes, chronic pain, neuropathy, and finding a great product at a fair price: all of those come into play. The neuropathy population has many of those things, and any patients with these symptoms who are cost sensitive and demand state of the art technology would be good candidates for the RevitaMed. One LymphaCare employee states, “it's like getting the Lexus model for the price of a Chevy". The RevitaMed Therapy System meets FDA guidelines and does not require a prescription.

RevitaMed products can be found by calling LymphaCare at 800-288-1801.

Posted by Industrial-Manufacturing at 04:12 AM | Comments (0)